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The store-operated calcium entry (SOCE) pathway is an important route for generating cytosolic 
Ca2+ signals that regulate a diverse array of biological processes. Abnormal SOCE seem to underlie 
several diseases that notably include allergy, inflammation, acute pancreatitis and cancer. 
Therefore, any modulator of this pathway is likely to have significant impact in cell biology under 
both normal and abnormal conditions. In this study, the FDA-approved drug library was screened 
for agents that share significant similarity in 3D shape and surface electrostatics with few, hitherto 
best-known inhibitors of SOCE. This has led to the identification of five drugs that showed dose-
dependent inhibition of SOCE in cell-based assay, probably through blocking SOCE pathway 
extracellularly. Of these drugs, leflunomide and teriflunomide could suppress SOCE significantly 
at clinically-relevant doses and this provides for an additional mechanism towards the therapeutic 
utility of these drugs as immunosuppressants. 
Few more compounds from each of the 4 different pharmacological classes were further tested 
using cell-based methods to find agents with more potent SOCE-inhibitory potency. Three 
candidates with better potency namely trequinsin, roflumilast N-oxide and vidofludimus, were 
identified. Of these compounds, vidofludimus which is known to be an inhibitor of the 
dihydroorotate dehydrogenase (DHODH) enzyme, proved to be the most potent (IC50~1.4µM) 
SOCE inhibitor among all the drugs tested, inhibitor of SOCE as it could suppress SOCE 
significantly at nanomolar dose. 
Next, selected drugs identified with SOCE suppressive ability were evaluated against the 
proliferation of different lung cancer cells namely H520, H1752, and LK2. In agreement with 
previous studies with bona fide SOCE inhibitors, the chosen drugs significantly reduced 
proliferation of those lung cancer cells.  
 
iii 
Although the possible contribution of the inhibition of the known targets of these drugs towards 
their anti-proliferative activity could not be ruled out, it was nevertheless indicative of the fact that 
their SOCE-inhibitory property was definitely implicated.  
This, in agreement with existing literature, hinted towards the fact that SOCE can be targeted to 
achieve potential therapeutic benefit against lung cancer and other cancer cells of epithelial origins.  
Of the drugs identified at the early phase of the present work to possess SOCE suppressive ability, 
teriflunomide is approved for multiple sclerosis (MS) which is believed to be autoimmune origin. 
The pro-drug of teriflunomide is leflunomide which is approved for managing rheumatoid arthritis. 
Since oligodendrocytes progenitor cells (OPCs) play important role in MS due to their myelin 
forming ability upon differentiation, SOCE was characterized in OPCs using single cell Ca2+ 
imaging approach and effect of some SOCE inhibitory compounds were then evaluated for any 
role in OPC differentiation. Employing different biochemical and imaging methods, AnCoA4, a 
known SOCE blocker was found to promote differentiation of OPCs. This finding could help to 
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1.1 Store operated calcium entry pathway 
Ca2+ is a versatile an intracellular messenger that controls a diverse range of biological 
processes including fertilisation, differentiation, growth and proliferation, gene transcription, 
contraction, exocytosis and cell death (Berridge et al. 2000; Carafoli 2002). With the help of 
various pumps and transporters which are often energized, cytosolic free Ca2+ concentration 
([Ca2+]i) is maintained at low (100-300nM) level under resting condition. A Ca2+ signal is 
effectively switched on with the transient increase of [Ca2+]i from the resting nanomolar level 
to a global maximum of ~1µM (Berridge et al. 2003). In order to generate such signals, cells 
secure the 'extra' Ca2+ from the internal stores (notably the sarcoplasmic or endoplasmic 
reticulum, SR or ER respectively but also from some other organelles such as lysosome, 
mitochondria, nucleoplasm etc.) as well as from the extracellular space. In excitable cells such 
as neurons, Ca2+ entry across the plasma membrane (PM) occurs mainly through voltage gated 
Ca2+ channels (VGCCs) following depolarisation of the PM. Non-excitable cells such as 
smooth muscle cells and immune cells essentially lack such VGCC-mediated Ca2+ entry. 
Instead, these cells employ several non-voltage-gated Ca2+ influx mechanisms that notably 
include the store operated Ca2+ entry (SOCE) pathway (Parekh 2010).  
SOCE, originally termed as the 'capacitative calcium entry (CCE)' (Putney et al. 2001), is 
triggered by the depletion of endoplasmic reticulum (ER) Ca2+ stores either by physiological 
or pharmacological means (Prakriya and Lewis 2015). Ca2+ entry via this pathway replenishes 
the depleted stores but emerging evidence suggests that it also can couple to specific biological 
processes (Kar and Parekh 2013; Putney 2005).  
Physiologically, activation of SOCE occurs in the wake of agonist stimulation of Gq/11 protein-
coupled receptors (for example, muscarinic M1 or M3 receptor) or certain growth factor 
receptors in the PM and this in turn activates phospholipase C isoforms (PLCβ, PLCγ). The 
latter then catalyses the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), a 
membrane bound phospholipid, into the second messengers, inositol 1, 4, 5- trisphosphate (IP3) 
and diacylglycerol (DAG). The latter is well-known to trigger the receptor-operated Ca2+ entry 
(ROCE) pathway through activation of members of the transient receptor potential family C 
(TRPC) channels and also known to activate protein kinase C (PKC) (Hofmann et al. 1999; 
Martin 2006). IP3 diffuses through the cytosol and binds to and activates inositol 1, 4, 5- 
trisphosphate receptors (IP3Rs) located within the membrane of the endoplasmic reticulum 
(ER). Opening of these channels allows Ca2+ to move down its concentration gradient from 
lumen of the ER into the cytosol and this leads to depletion of the ER luminal Ca2+ stores 
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(Bootman et al. 2001). The latter which is often termed as 'the store depletion' in turn triggers 
SOCE, thereby allowing a slow and sustained Ca2+ entry across the PM. As Ca2+ store becomes 
replenished, SOCE is terminated (Smyth et al. 2010). 
Activation of SOCE surely requires depletion of internal Ca2+ stores but it appears to be 
independent of how stores are depleted. Thus apart from physiological means (for instance, 
stimulating cell surface receptors that produce IP3), SOCE can be triggered pharmacologically 
by using tools that directly (for example, ionomycin, a Ca2+ ionophore or TPEN, a luminal Ca2+ 
chelator) or passively (for example, thapsigargin - an inhibitor of the the sarco/endoplasmic 
reticulum Ca2+-ATPase (SERCA) pump) deplete the internal Ca2+ stores (Parekh and Putney 









Figure 1.1 Store-operated calcium entry. Binding of an agonist (Ag) to receptor (R) activates 
phospholipase C (PLC) that hydrolyzes PIP2 and produces IP3. The latter then open IP3Rs 
within the ER membrane, via which Ca2+ is rapidly drained into the cytosol from the lumen of 
the ER. The latter becomes emptied and thereby leads to the activation of SOCE in the PM. 
SOCs are also activated by the consequent reduction of ER luminal [Ca2+]i. SOCE can be 
activated by chelating intracellular Ca2+ with EGTA, inhibiting SERCA pumps with 
thapsigargin, releasing Ca2+ from the ER with ionomycin, or chelating intraluminal Ca2+ with 





1.1.1 Proteins underlying the SOCE pathway 
Since the first proposal of SOCE pathway (Putney 1986), its molecular mechanism including 
the identity of the channel protein(s) that mediate the Ca2+ entry and how the channels 
underlying SOCE sense and respond to the store depletion remained elusive for many years. 
Till 2006, some Ca2+-permeable members of the mammalian transient receptor protein (TRP) 
family (notably TRPC1, TRPC3 and TRPV6) were among the most widely-proposed 
candidates to mediate the SOCE, although none of them when expressed heterologously fully 
match the biophysical properties of ICRAC (Ca2+ release-activated Ca2+ current) and for some of 
the candidates, it was even not clear whether their activation was truly store-dependent 
(Prakriya and Lewis 2015). The mechanism coupling ER Ca2+ depletion to CRAC channels 
activation, despite over a dozen proposed schemes, also remained largely unknown for a long 
time till 2005.   
In 2005, a real breakthrough happened in the SOCE field with two  research groups led by 
Meyer (Liou et al. 2005) and Stauderman (Roos et al. 2005) independently establishing the 
same protein namely STIM1(stromal interaction molecule 1) as an ER membrane protein that 
senses the change in ER Ca2+ levels. Another breakthrough occurred in the following year with 
the identification of a  protein namely Orai1 (Prakriya et al. 2006) or CRACM1 (Ca2+ release-
activated Ca2+ modulator 1) (Vig et al. 2006) as the pore-forming subunit of the CRAC channel 
in two independent studies. With the discovery of STIM and Orai, the molecular mechanism 
of CRAC channel activation has been extensively studied worldwide and we now have a basic 
understanding of the choreography of molecular events that begins with Ca2+ release in ER and 
culminates in Ca2+ entry through CRAC channels. 
STIM1 
STIM1is a 77kDa type 1 membrane protein, the majority of which is located in the ER 
membrane though up to 25% of STIM1 expression can be identified in the PM (Lewis 2007; 
Zhang et al. 2005). In vertebrates there are two STIM homologues; STIM1 and STIM2 (Liou 
et al. 2005). STIM1 is composed of multiple domains that include an unpaired EF-hand and 
sterile α-motif (SAM) domain that reside within the ER lumen at the N-terminal region of the 
protein and a coiled-coil (CC)/ezrin-radixin-moesin (ERM), serine/proline-rich and lysine-rich 
domain residing within the cytosol at the C-terminal region of the protein. Several amino acids 
from both EF hands come together to form a hydrophobic cleft that interacts with, and 
stabilizes, the hydrophobic, helix-rich SAM domain (Stathopulos et al. 2008).  
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STIM1 is predicted to sense the level of Ca2+ within the ER through its unpaired EF-hand 
domain (Zhang et al. 2005). 
STIM2 
STIM2 is also a type 1 membrane protein that shares 66% sequence homology with STIM1 
(Williams et al. 2001). This protein also has an EF hand and SAM domain within the ER and 
a CC, serine/proline and lysine-rich domain reside within the cell cytosol at the C-terminal 
region of the protein (Williams et al. 2001; Zheng et al. 2008). Unlike STIM1, STIM2 is mainly 
expressed in ER membrane whereas the former also expresses in the PM (Zheng et al., 2008). 
Likewise, STIM1, STIM2, also can be translocated to ER-PM junctions in response to ER 
depletion and can activate SOCE through interaction with Orai1. However, STIM2 only 
respond to little decreases in ER-Ca2+ level (Brandman et al., 2007).  
Orai1 
Orai1 is a 33kDa protein with four transmembrane domains (TM1-TM4) located within the 
PM with both N- and C-termini facing towards the cytosol (Prakriya et al. 2006). In vertebrates 
there are three Orai homologues namely Orai1, Orai2 and Orai3 (Feske et al. 2006). In 2006, 
Orai1 was first identified as an essential component of SOCE (Feske et al. 2006; Zhang et al. 
2006). T cells from patients with severe combined immunodeficiency (SCID) syndrome failed 
to activate SOCE following store depletion (Feske et al. 2005) which was later attributed to a 
single point mutation (R91W) in Orai1 (Feske et al. 2006). Furthermore, transfection with wild-
type Orai1 in cells derived from SCID patients restored SOCE. 
Orai2 
Orai2 forms complex with STIM1 in HEK293 cells to enhance SOCE though to a lesser extent 
than Orai1 (Mercer et al. 2006). 
Orai3 
Unlike Orai1 and Orai2, Orai3 usually does not involve in SOCE pathway (Mercer et al. 2006; 
DeHaven et al. 2007). Mutation of Orai3 gene in HEK293 cells had no effect on SOCE 
(Mignen et al. 2008). However, Orai3 may be involved in SOCE in some extent as Orai3 
expression in Orai1 knockdown cells rescued SOCE (Mercer et al. 2006).  
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Figure 1.2 demonstrates the activation of the STIM proteins, the subsequent coupling of 
STIM1 to Orai1, and the consequent structural rearrangements that gate the Orai channels into 
the open state to allow Ca2+ permeation into the cell. 
 
Figure 1.2 Hypothetical model for the coupling of STIM1 and Orai1. After store depletion, 
STIM1 proteins lose the Ca2+ bound to the luminal EF-hand and undergo a conformational 
change from the inactive, tight state (A) to the active, extended state (B). Thereby, the crossing 
angle of the TM helices alters and the inhibitory, intramolecular clamp between CC1a1 and 
CC3 is released. (C) Extension of STIM1 proteins leads to the interaction with Orai1, is 
accompanied by oligomerization of STIM1 proteins to larger aggregates than dimers and 
involves the CC3 domains. Image is taken from Derler et al. 2016. 
TRPC1 
TRPC1, a 90kDa PM protein, has been implicated in SOCE in many cell types (Parekh and 
Putney 2005). For instance, knockout of TRPC1 in submaxillary acinar mouse cells caused an 
80% reduction in SOCE (Liu et al. 2007). However, role of TRPC in SOCE pathway is still 
unclear as several studies have shown that TRPC1 is not involved in SOCE. 
Most of the controversy surrounding the role of TRPC1 as a SOCE is due to its well-established 
role as receptor-operated calcium channel (ROCC), a non-voltage gated Ca2+ permeable 
channel activated by agonists acting on a range of G-protein-coupled receptors. However, 
studies showed TRPC1 can function as both a ROCE and a SOCE in a STIM1 dependent 
manner (Alicia et al. 2008). TRPC1 activates SOCE by interacting with STIM1 and this 
interaction disrupted upon knockdown of STIM1, which indicated TRPC1 is STIM1 dependent 
(Yuan et al., 2007). TRPC1 forms complex with STIM1 in ER-PM junction area when ER-
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Ca2+ is depleted (Huang et al. 2006). Studies also have shown that following store depletion, 
the interaction between STIM1 and TRPC1 is increased (Huang et al. 2006; Lopez et al. 2006; 
Alicia et al. 2008; Ng et al. 2009). 
1.1.2 SOCE channel vs CRAC channel 
Now its substantially evident that STIM1 acts as the ER Ca2+ sensor that signals store depletion 
to Orai1, the pore forming subunit of the SOCE channel, together forming the elementary unit 
of SOCE (Luik et al. 2006). However, before these discoveries, TRPC1 was a sole candidate 
for SOCE channel although its role in SOCE still remains controversial (Alicia et al. 2008). 
Variants of SOCE channels have been described in different cell types, based on the distinct 
biophysical properties of the Ca2+ current that underlies SOCE (Roos et al. 2005; Cheng et al. 
2008). For instance, a popular notion exists in this field that the ICRAC, which is highly selective 
to Ca2+ current, can be interceded through Orai1 channels (Prakriya et al. 2004; Parekh and 
Putney 2005), on the other side, the store-operated Ca2+ current (ISOC), a non-selective Ca2+ 
current is mediated through TRPC1 channels (Liu et al. 2007). Moreover, in some cases, cells 
could form a ‘complex of STIM1, Orai1 and TRPC1’ to constitute SOCE (Ong et al. 2007; 
Liao et al. 2009; Cheng et al. 2008). 
However, till now the best characterised current representing the SOCE is the ICRAC which was 
first recorded in T lymphocytes (Lewis and Cahalan 1989) and mast cells (Matthews et al. 
1989) following physiological stimulation with antigen or agonists. Subsequently, similar 
currents were recorded following pharmacological (e.g. thapsigargin (Tg)), IP3 or ionomycin 
mediated) depletion of intracellular Ca2+ stores in Jurkat T cells (Zweifach and Lewis 1993) 
and RBL cells (Hoth and Penner 1992) establishing store-depletion as the proximal stimulus 
for channel activation. ICRAC is characterized by its high selectivity for Ca2+, an inwardly 
rectifying current-voltage relationship, and an extremely small single-channel conductance in 









1.1.3 Mechanism underlying CRAC channels activation 
Under resting condition, STIM1 is homogeneously distributed within the ER membrane. Cell 
surface stimulation of the PLC-coupled receptors or pharmacological manipulation (for e.g. 
Tg, ionomycin or TPEN) causes loss of Ca2+ from the ER lumen and this results in Ca2+ 
dissociation from the luminal EF hand (helix loop helix structural domain) of STIM1 (Liou et 
al. 2005; Zhang et al. 2005). This reduces the intramolecular interactions between the EF hands 
and the SAM domain leading to the partial unfolding of STIM1 (Stathopulos et al. 2008). 
STIM1 oligomers form due to the homotypic interaction between exposed hydrophobic SAM 
domains (Stathopulos et al. 2008). The oligomers then migrate to specialized endoplasmic 
reticulum–plasma membrane (ER-PM) junctions (Liou et al. 2007), which are located within 
10-25 nm of the PM (Wu et al. 2006). Olimerization alone leads the STIM1 accumulation at 
ER-PM junction regardless of the presence of a full Ca2+ store, however, this is not enough to 
activate Orai1 (Park et al. 2009). Although it is still not clear what precisely pushes clustered 
STIM1 proteins to the cell periphery but surely this does not require Orai1 (Wu et al. 2006). 
Nevertheless Orai1–STIM1 interactions stabilize STIM1 at the PM (Park et al. 2009). A 
cytosolic region of STIM1  (the CRAC activation domain, CAD; also known as the STIM1 
Orai1-activating region, SOAR) has been established to be essential for CRAC channel 
activation (Muik et al. 2009). This domain is probably exposed on STIM1 oligomerization and 
binds directly to both the N and C termini of Orai1 to open the channels (Park et al. 2009). 

















Figure 1.3 Possible gating mechanism of CRAC channels. In cells with full Ca2+ stores, 
STIM1 is homogenously distributed in the ER with its EF hand occupied with Ca2+. Orai1 is 
dispersed throughout the PM. Upon stimulation with physiological or pharmacological means, 
the Ca2+ content of the store falls. Ca2+ dissociates from STIM1 and this results in STIM1 
oligomerization and subsequent migration to ER-PM junctions. At this point, STIM1 captures 
diffusing Orai1 channels. Interaction between the amino and carboxyl termini of Orai1 with 
the CAD of STIM1 leads to CRAC channel opening. The figure has been taken from Parekh 
2010. 
 
1.1.4 Physiological role of SOCE pathway  
SOCE in non-excitable cells provides for a means to replenish the internal Ca2+ stores for next 
round of Ca2+ release. This mechanism holds true for the excitable cells such as neurones as 
well (Wu et al. 2011). However, apart from this fundamental role, Ca2+ emanating from the 
open CRAC channels form microdomains near the vicinity of the open pore of these channels, 
largely due to poor diffusibility of Ca2+ in cytosol. Intriguingly, interesting links have been 
established with the store depletion and cAMP signalling where interplays between 
STIM1/Orai1 and Ca2+ sensitive adenyl cyclases have been reported (Lefkimmiatis et al. 2009).  
The 'local' Ca2+ signals generated by SOCE pathway seem to couple to specific biological 
processes such as regulation of various Ca2+-sensitive enzymes as well as activation of certain 
genes. The notable example of the latter includes activation and nuclear translocation of the 




In resting cells, NFAT proteins are phosphorylated and reside in the cytoplasm; on stimulation, 
during a sustained elevation of Ca2+, they are dephosphorylated by calcineurin and translocated 
to the nucleus. Once in the nucleus, NFAT proteins become transcriptionally active and bind 
to consensus DNA sites, therein controlling the transcription of target genes (Fig. 1.4). On 
cessation of Ca2+ signalling, NFAT proteins are re-phosphorylated and translocated back to the 








Figure 1.4 SOCE drives NFAT translocation into nucleus. 
The figure is taken from Parekh 2010. 
1.1.5 Abnormal SOCE pathway in diseases 
Aberrant SOCE pathway over the years has been implicated in several diseases including 
severe combined immunodeficiency (SCID) disorders, allergy, inflammatory bowel disease, 
neurodegenerative diseases, and cardiovascular disorders (Parekh 2010; Roberts-Thomson et 
al. 2010). STIM/ORAI-mediated SOCE plays important roles in the proliferation and 
metastasis of cancer cells. The exact function and mechanism are complicated and context-
dependent (Mukherjee and Brooks 2014; Roberts-Thomson et al. 2010), such complications 
are summarized in table 1.1.  
SOCE in severe combined immunodeficiency (SCID) 
In severe combined immunodeficiency SCID diseases, Icrac is absent and T cell activation is 
severely impaired (Feske et al. 2005). SCID patients have the genetic defect to a region of 
approximately 74 genes on chromosome 12. ORAI1 was mapped to the SCID defect region in 
chromosome 12. The SCID sufferers had a single point mutation (R91W) in ORAI1 within the 
coding region (figure 03). This mutation led to the complete loss of ICRAC (Feske et al. 2006). 
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SOCE in allergic disorders  
Excursive mast cells activation is linked to a range of allergic disorders including asthma, 
rhinitis, eczema and nasal polyposis (Peters-Golden et al. 2006). Nasal polyposis is an 
inflammatory disease of the upper respiratory tract. The polyps are rich in mast cells and 
eosinophils (Di Capite et al. 2009). However, presence of Icrac in polyps has been demonstrated. 
Partial blocking of CRAC channel has been proven as effective in dampening down mast-cell 
activation (Di Capite et al. 2009). 
SOCE in antitumor immunity regulation 
SOCE regulates antitumor immunity by inducing the activation of Ca2+-dependent 
transcription factors, such as NFAT, cAMP response element-binding protein (CREB) or 
activating transcription factor (ATF) 2. These factors are essential for the development and 
normal function of immune cells (Kreideweiss et al. 1999).  SOCE also promotes the 
production of cytokines and chemokines that can directly kill cancer cells. 
SOCE in apoptotic cell death, proliferation and metastasis of cancer cells 
Inhibition of SOCE through STIM1 knockdown shows the upregulation of p21 and the 
downregulation of Cdc25C, cyclin E, cyclin D, CDCK2 and CDCK4, which eventually elicits 
cell cycle arrest (Chen et al. 2011) . STIM1 and Orai1 knockdown impair adhesion turnover 
and cell migration (Yang et al. 2013; Chen et al. 2011; Yang et al. 2009). Due to deviant SOCE, 
Ca2+-regulated protease calpain and the cytoplasmic kinase Pyk2 become activated, which 
essentially regulate the focal adhesion dynamics of migratory cervical cancer cells (Chen et al. 
2011). STIM1 over expression enhances the colorectal cancer cells migration via an increase 
in the expression of cyclooxygenase-2 (COX-2) and the production of prostaglandin E2 
(PGE2) (Wang et al. 2015).  
SOCE in tumour angiogenesis  
SOCE promotes the recruitment of new blood vessels, or angiogenesis through regulating the 
production of vascular endothelial growth factor (VEGF), which is critical for the formation of 
new blood vessels (Chen et al. 2011). Ca2+-dependent activation of NFAT also regulates the 
expression of key molecules such as tissue factor (TF) and COX-2. These molecules are very 
important for endothelial cell migration, tube formation and angiogenesis (Armesilla et al. 
1999; Hernández et al. 2001). 
Table 1.1 below provides some evidence implicating SOCE and its underlying protein players 
in promoting cancerous features in various cell types.  
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Table 1.1 Aberrant SOCE in different cancer cells   
Ca2+ channel Cancer cell type Possible 
mechanisms 
Major effects Reference 
STIM1-Orai1 Cervical cancer 
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1.1.6 Pharmacology of SOCE/CRAC channels 
The complexity of CRAC channel activation process, such as protein-protein and ER-PM 
interactions, opens up potential scopes for pharmacological modulation of the SOCE pathway 
(Luik and Lewis 2007). Historically, few inhibitors have been widely used for the 
characterisation as well as evaluating the biological roles of CRAC channels in various tissues. 
However, their precise mechanisms of action on CRAC channel remains largely unclear 
(Jairaman and Prakriya 2013).  
Given the emerging roles of the CRAC channels in the pathogenesis of various diseases 
mentioned earlier (Parekh 2010), there have been interests by academics as well as 
pharmaceutical companies to develop specific inhibitors of these channels and in recent time, 
there have been few synthetic small molecules with improved potency and selectivity towards 
CRAC channels (Putney 2010; Prakriya and Lewis 2015). Few of these molecules are claimed 
to be selective for particular proteins like Orai1. Nevertheless, even for most of these new 
generation CRAC modulators, the precise mechanism of action remains insufficiently 
understood. Most common modulators of SOCE or CRAC channels are summarised in table 








Table 1.2 Common modulators of SOCE/CRAC channels 
Category Compound Effect Mechanism IC50 Reference 
 La3+ Inhibition Pore blockade 3358nM, (SOCE),   
240nM,(Orai1), 
470nM,(Orai3) 
(Ross and Cahalan 
1995; Yamashita and 
Prakriya 2014) 
 Gd3+ Inhibition Pore blockade 18–28 nM, (SOCE) 
46 nM, (ICRAC) 
(Ross and Cahalan 
1995; Yeromin 2004) 




Unknown 3µM, (ICRAC),  
4µM, (Orai1) 
(Peinelt et al. 2008; 
Prakriya and Lewis 
2001) 
 2-APB Inhibition Unknown 10µM, (ICRAC) 8µM, 
(Orai1) 
(Prakriya and Lewis 
2001;Peinelt et al. 
2008) 
 2-APB Activation Direct channel 
activation? 
24µM, (Orai3, ICRAC) 
15µM, (Orai3,SOCE) 





Inhibition Unknown 90–170 nM (ICRAC) (Goto et al. 2010) 
 ML-9 Inhibition Inhibits STIM 
translocation 
16µM (SOCE) (Smyth et al. 2008) 
 BTP2 
(YM58483) 
Inhibition Unknown 100-150nM (SOCE; 
acute), 6–12nM 
(SOCE; 24 h pre-
incubation) 0.5–
2.2µM (ICRAC; acute) 
(Ishikawa et al. 2003; 
Takezawa et al. 2006; 
Zitt et al. 2004) 
 Synta66 Inhibition Unknown 3µM (ICRAC) (Ng et al. 2008) 
Small 
molecules 
Econazole Inhibition Unknown 0.6–14µM (ICRAC)  ( Franzius et al. 1994) 
 SK&F96365 Inhibition Unknown 4µM (ICRAC)  (Franzius et al. 1994) 
 GSK-7975A 
GSK-5503A 
Inhibition Unknown 4µM (Orai1) (Derler et al. 2013) 
 RO2959 Inhibition Unknown 25nM (Orai1) 
530nM (Orai3) 
(Chen et al. 2013) 
 AnCoA4 Inhibition Inhibits Orai1 1–10µM (Orai1)  (Sadaghiani et al. 
2014) 
Antibodies monoclonal Ab Inhibition Inhibits Orai1 1nM (Orai1)  (Lin et al. 2013) 
 Anti-Orai1 mAb Inhibition Inhibits Orai1  <1nM (SOCE)  (Cox et al. 2013) 
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1.2 Virtual Screening 
Virtual screening is a cost-efficient and time-efficient high-throughput method used to select 
promising lead candidates from a vast chemical space based on information from either a) the 
structure of the ligand binding site (LBS) of a receptor or b) the chemical structure of known 
ligands. The former is termed as structure-based virtual screening (SBVS) while the latter is 
called as ligand-based virtual screening (LBVS). Virtual screening methods have been widely 
used in the industry as well as in the academia, parallel to wet high throughput screening for 
finding new chemical scaffolds as hits/leads towards developing new therapeutic entities.  
Since SOCE channel is implicated in various diseases mentioned above, there has been 
legitimate interest in pharmaceutical and academic communities towards developing selective 
inhibitors of this pathway. In recent time, there have been developed few synthetic small 
molecules with improved potency and selectivity towards CRAC channels (Putney 2010; 
Prakriya and Lewis 2015). 
Rational ligand-based in silico approach (Yan et al. 2015) approach can be utilised to find new 
molecules as SOCE inhibitor through exploiting the structures of few existing CRAC 
inhibitors. Since the database of the officially approved drugs is publicly available therefore 
whether any drug with hitherto no known effect on SOCE pathway can be identified through 
such in silico ligand-based approach. The latter thus essentially entails a drug repositioning 












1.3 Primary aims and objectives 
Based on the studies done by various groups so far, it is perhaps fair to say that SOCE/CRAC 
channels are valid therapeutic targets against some diseases that notably include some cancer 
and few that stem from autoimmunity (Parekh 2010; Feske 2019). Although to date, there are 
several small molecule inhibitors of SOCE developed with few being in early phase of clinical 
trial (Stauderman 2018), most of the existing molecules suffer from the lack of adequate 
selectivity, potency as well as clear mechanism of actions. Few such molecules also have 
effects on other channel, transporters and pumps and cytoskeleton (Prakriya and Lewis 2015), 
and thus only useful as tool compounds whilst those in early phase of clinical trials may or may 
not succeed in successfully completing final phase of clinical trials. Therefore, the need for 
identifying new scaffolds against SOCE/CRAC channels remains still valid for future 
developing of more specific inhibitors with greater potency and with the mechanism of action 
deciphered. In recent time, drug repurposing has been an attractive theme towards finding 
novel use of approved or investigational drugs at substantially reduced cost, time and risk 
(Schein 2019). Besides, such approach can also potentially reveal any beneficial or unwanted 
off target effect of a known agent. Apart from phenotypic screening, virtual screening and other 
in silico approaches have been proving to be useful techniques for drug repurposing 
endeavours. 
The primary aims of the present work include: 
(a) To find whether any of the existing drug(s) possess comparable similarities in 3D shape 
and surface electrostatics with those of few known SOCE modulators and verifying through 
bioassay the possible SOCE modulatory effect of few of the best hits from the virtual screening.  
(b) If any drug candidate(s) available from (a) then exploring more drugs/analogues of similar 
class against SOCE pathway. 
(c) Testing the best performing SOCE modulatory drugs or compounds in biological 




























2.1.1 cell culture 
Cell lines and their sources 
Cell lines were kindly provided by different institute across the globe: rat basophilic leukemia-
1 (RBL-1) cells (passage 11) from Professor Anant B. Parekh, Oxford University, Oxford, UK; 
SH-SY5Y cells (passage 20) from Professor Robin Irvine, University of Cambridge, 
Cambridge, UK; human jurkat T cells (passage 2) from Dr Heike Laman, University of 
Cambridge, Cambridge, UK; HEK293 cell line with an inducible mCherry-STIM1-T2A-
Orai1-eGFP from Dr. Chan Young Park, UNIST, South Korea; HeLa cells stably expressing 
the NFAT1(1-460)-GFP fusion protein from Professor Patrick Hogan, La Jolla Instiute for 
Allergy and Immunology, CA, USA; and lung cancer cell lines from Dr. Graham Ladd, 
University of Cambridge, Cambridge, UK. 
Cell medium and other elements 
Dulbecco's Modified Eagle Medium (DMEM), Ham’s F 12 media with L-Glutamine, 0.25% 
trypsin media, RPMI medium, fetal bovine serum, fetal calf serum and antibiotic antimycotic 
100X mix, were used and bought from Life Technologies Ltd (Paisley, UK). Glass bottom 













2.1.2 Drugs and compounds 
Table 2.1 List of drugs and compounds tested against SOCE 
Name Supplier Name Supplier 
Leflunomide Tocris, UK Terazosin  Sigma-Aldrich 
Teriflunomide Tocris, UK Flutamide Sigma-Aldrich 
Tolvaptan Tocris, UK Roflumilast Sigma-Aldrich 
Omeprazole Sigma-Aldrich Conivaptan  Selleckchem 
Lansoprazole Sigma-Aldrich Lixivaptan Cayman Chemical 
Rufinamide Sigma-Aldrich Mozavaptan Cayman Chemical 
Prazosin  Sigma-Aldrich OPC 21268 Tocris, UK 
STK485210 Selleckchem Piclamilast Sigma-Aldrich 
PF 3716556 Tocris, UK 3,4-Bis Roflumilast Biosynth Carbosynth 
Roflumilast N-oxide MedChemExpress Trequinsin Tocris, UK 
BR1138 Tocris, UK Cilostamide Tocris, UK 
BRL 50481 Tocris, UK Rolipram Tocris, UK 
SR 49059 Sigma-Aldrich ML390 Selleckchem 
Brequinar Tocris, UK Atovaquone Tocris, UK 
Vidofludimus Selleckchem 9090672 Selleckchem 
9099120 Selleckchem SCH 28080 Tocris, UK 
Apremilast MedChemExpress Bay736691 Sigma-Aldrich 










2.1.3 Oligodendrocyte progenitor cells (OPCs) isolation and culture 
2.1.3.1 Animals 
For the experiments, timed pregnancies of the inbred Sprague-Dawley rats from Charles River 
UK, Ltd (Kent) were used. The rats were kept in the local animal facility (Dept. of Veterinary 
Medicine, University of Cambridge, UK) in a 12h light/dark cycle until the pups reached an 
age of postnatal day (P) 2. 
2.1.3.2 Medium and solutions 
Dissociation solution 
Hibernate media (Gibco)  
Papain (Worthington Biochem): 40µl/ml 
DNase I Type IV (Sigma): 10µl/ml 
L-Cysteine (Sigma): 2mM 
Ovomuccoid 
L-15 media (Gibco) 
soybean trypsin inhibitor (Sigma): 1 mg/ml 
BSA V (Sigma): 50µg/ml 
DNase I Type IV (Sigma): 40 µg/ml 
Dissection media 
DMEM/F-12 (Gibco) 
10µl/ml of Penicillin/Streptomycin (Sigma) 
Mixed Glia Medium (MGM) 
DMEM/F-12 (Gibco) 
10% FCS (BioSera) 
Penicillin/Streptomycin (Gibco): 10µl/ml 
OPC Medium 
DMEM with L-Glutamine and high Glucose 
BSA fraction V (Sigma): 330µg/ml 
Sodium selenite (Sigma): 0.25mg  
Progesterone (Sigma): 60ng/ml 
Sodium selenite (Sigma): 40ng/ml 
Putrescine (Sigma): 16µg/ml 
Insulin (Gibco):10µg/ ml  
Sodium pyruvate (GIBCO): 1mM 
Penicillin/Streptomycin (Gibco): 10µl/ml 
Apo-transferrin (Sigma): 50µg/ ml  
Milteny washing buffer (MWB) 
BSA (Sigma): 0.5% 
EDTA (ThermoFisher): 2mM 
Sodium pyruvate (GIBCO): 2mM 
PBS (Gibco): 10% 
pH: 7.3 
Deionized water  
Trituration solution 
Hibernate media supplemented with 2% B27 
Sodium-pyruvate: 2mM 
Pluronic™ F-68 (Gibco): 1% 
Differentiation medium 
OPC medium supplemented with daily 
addition of 40ng/ml tri-iodothyroxine (T3) 
(Sigma)  
Proliferation medium 
OPC medium supplemented with daily 


















2.1.4 Other chemicals and compounds 
Fura-2/AM (Molecular Probes), Ionomycin (Calbiochem Darmstadt, Germany), MnCl2 
(Sigma-aldrich), thapsigargin (Sigma-aldrich), Hank’s Balanced Salt Solution (HBSS, with or 
without Ca2+), carbachol (Sigma-aldrich), nifedipine (Tocris), SKF96365 (Tocris), potassium 
chloride (Sigma-aldrich), and Ca2+ solution (Sigma-aldrich), BTP2 (Tocris), 1-Oleoyl-2-







Antigen  Host Dilution Supplier 
Olig2 goat 1:500 R&D system 
Olig2 rabbit 1:500 Millipore 
GFAP rabbit 1:1000 DAKO 
CD11b mouse 1:200 Abcam 
NG2 rabbit 1:200 Millipore 
MBP rat 1:500 Serotec 
PCNA mouse 1:500 Santa Cruz 
CNPase mouse 1:500 Thermo Scientific 
Conjugate Reactivity Dilution Supplier 
Alexa Fluor 488 goat 1:500 Invitrogen 
Alexa Fluor 568 rabbit 1:500 Invitrogen 
Alexa Fluor 568 rat 1:500 Invitrogen 
Alexa Fluor 647 mouse 1:500 Invitrogen 
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2.2 Methods 
2.2.1 Ligand-based screening of database of officially-approved drugs 
The method reported by Naylor et al. 2019 was largely followed. Latest version of the 
eDrugs3D database were used that contains 1822 molecular structures comprising of 3D 
representations along with isomers of total 1557 FDA-approved drugs (Pihan et al. 2012). For 
each drug, up to 100 conformers were generated using OMEGA33 (version 2.5.1.4, OpenEye 
Scientific Software, Santa Fe, NM, USA). The query molecules (SOCE inhibitors) such as 
BTP2, Synta66, Pyr6 and AnCoA4 were drawn and energy-minimized with the Merck 
Molecular Force Field 94 using the ChemBioOffice Ultra 11.0 (Cambridge Soft Corporation, 
Cambridge, MA, USA). The energy-minimized structures of the query molecules were then 
used for generating the 3D queries. Each of the queries was then utilized to scan the above-
mentioned conformer library generated from eDrugs3D by using Rapid Overlay of Chemical 
Screens (ROCS)35 (version 3.2.1.4, OpenEye Scientific Software, Santa Fe, NM) and all 
resulting hits were ranked with Tanimoto Combo (TC) score that represents a numerical sum 
of the shape Tanimoto (maximum value = 1) and scaled colour Tanimoto score (maximum 
value = 1).  
The size of the screening output was limited to 500 molecules. The ROCS output was then 
used as an input to EON (version 2.2.0.5, OpenEye Scientific Software, Santa Fe, NM) for re-
ranking the aligned molecules on the basis of their electrostatic similarity with the cognate 
query ligand. For this, the EON Tanimoto combo (ET combo) score was used which is the sum 
of the EON Poisson-Boltzmann and EON Shape Tanimoto scores. Default parameters were 
used throughout. VIDA (version 4.3.0.4, OpenEye Scientific Software, Santa Fe, NM) was 
used to visualize and analyze the outputs from screening done with ROCS and EON. VIDA 
and MacPyMol (version 1.7.2.1) were used for molecular representations.  
For each query molecule, each hit molecule was visually inspected using VIDA and shortlisted 
10 candidates on the basis of several aspects including their similarity in electrostatic 
isopotential contour surfaces (EON-generated) with the cognate bait, their TC score and ET_pb 
score, their rank and frequency of appearing within the top 100 hits in ROCS as well as EON 
based screening, previous reported activity on calcium signalling and availability. The chosen 
molecules were purchased for bioassay. The drugs were dissolved in Ca2+-free Hank’s balanced 
salt solution (HBSS) or 10% DMSO. 
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All computational works were done in a Dell™ Precision Tower 7810 workstation (Intel® 
Xeon® Processor E5-1650 V3, 6 core, 3.5 GHz, 32GB RAM) run with 64-bit Windows 7 
Professional as the operating system. 
2.2.2 Cell culture 
RBL-1 cells, SHSY-5Y cells, HEK-293 cells and lung cancer cells were cultured in high 
glucose DMEM medium with the F-12 nutrients mixture, supplemented with 10% (v/v) fetal 
bovine serum, 2 mM L-glutamine and 1% (v/v) antibiotic/antimycotic mixture in humidified 
atmosphere with 5% CO2 and 95% air at 37°C. Cells were kept in 75cm2 flask and passaged 
at least once in a week after reaching ~90% confluence. In preparation for the passage of the 
cells, DMEM and trypsin media were pre-warmed at 37°C. Cell medium from the flask was 
aspirated and cells were detached from the flask through addition of 2/3ml of trypsin. After 2/3 
min, the flasks were gently shaken to allow complete detachment of adhered cells and then 
trypsin was neutralized by adding 8-10ml of DMEM. The cell suspension was then gently 
pipetted few times before it was centrifuged at 800 rpm for 5 minutes after which the 
supernatant was discarded, and the cell pellet was re-suspended in DMEM (10ml). The 
resultant cell suspension was used for seeding of cells into flasks and onto glass bottom dishes 
(10mm) as required for Ca2+ and confocal imaging. 
Human jurkat T cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) fetal 
calf serum. Cells were kept in 75cm2 flask and passaged at least once in a week after reaching 
~90% confluence. Glass bottom petri-dishes (10mm) were coated with PDL before seeding the 










2.2.3 Confocal Microscopy  
STIM1-Orai1 oligomerization assay 
HEK293 cells with an inducible mCherry-STIM1-T2A-Orai1-eGFP were plated onto sterilized 
cover slips and maintained in complete DMEM. STIM1-mCherry and Orai1-GFP protein were 
induced through tetracycline (2-5µM) treatment 12-16 hours before the experiment. Cells were 
washed with HBSS and incubated for 30-40 minute with the respective compounds and vehicle 
followed by 2µM of Tg treatment for 5 min. Cells were fixed with ice cold methanol (100%) 
for 15 min at -20°C. Cells were then washed twice with PBS and treated with DAPI (1:1000 
in PBS) for 5 minutes followed by washing in PBS for 10 min. 
Confocal images were acquired using a Leica SP5 microscope equipped with a Plan 
Apochromat 63x/NA1.4 oil immersion objective. The excitation wavelengths (ex) and 
emission filters (em) were as follows: DAPI, ex 364 nm/em 385-470 nm; Orai1-GFP, ex 488 
nm/em 500-515 nm; STIM1-mCherry, ex 543 nm/em 610 nm. Acquired images were 
processed using the ImageJ (National Institutes of Health). Acquired images were processed 
using the ImageJ (National Institutes of Health). For quantification of STIM1-mCherry and 
Orai1-GFP puncta formation, the puncta were selected as spots of high fluorescence intensity 
ranging from approx. 0.5 to 1.0µm in diameter and their number was determined as per 
previously published method ((Yazbeck et al. 2017). 
 
NFAT translocation assay 
HeLa cells stably expressing the NFAT1(1-460)-GFP fusion protein (Gwack et al. 2006) were 
grown on glass bottom petri-dishes. Cells were then washed with HBSS and incubated for 30-
40 minute with the respective compounds and vehicle followed by treatment of 1µM 
ionomycin and 2µM Tg for 40 min and 10 min respectively. Cells were then washed twice with 
PBS and treated with DAPI (1:1000 in PBS) for 5 minutes followed by washing in PBS for 10 
min. Confocal images were acquired using a Leica SP5 microscope equipped with a Plan 
Apochromat 63x/NA1.4 oil immersion objective. The excitation wavelengths (ex) and 
emission filters (em) were as follows: DAPI, ex 364 nm/em 385-470 nm and NFAT1(1-460)-
GFP, ex 488 nm/em 500-515 nm. Images captured were processed using imageJ software. 
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For the quantitative assessment of the ionomycin and Tg induced nuclear translocation of 
NFAT1(1-460)-GFP in HeLa cells with or without drug/BTP2 pre-treatment, NFAT-GFP 
fluorescence intensity ratio of nuclear to cytosol was followed.  
 
2.2.4 Cell proliferation assay for lung cancer cells 
Lung cancer cell line: LK2, H520, H1792 were seeded at a density of 2500 cells/well in a clear 
flat bottom 96-well plate (Corning). After 24 hours, cells were exposed to test compounds or 
vehicle, as indicated, and were incubated for 72 hours. After 72 hours incubation, 5µl of Cell 
Counting Kit-8 (CCK-8, Sigma, UK) was added to each well and the cells were incubated for 
an additional 2-3 hours at 37°C in the dark. The absorbance of each well was measured using 
a Mithras LB940 microplate reader (Berthold Technologies, Germany) with an excitation of 
450 nm. The amount of formazan formed is directly proportional to the number of viable cells. 
















2.2.5 OPCs isolation using mixed glia culture (MGC) method 
OPC cultures were prepared from neonatal (P0-P2) Sprague-Dawley rats as described 
previously by McCarthy and de Vellis, 1980 (Mccarthy 1980). The overall procedure is briefly 
described below. 
Sprague-Dawley rats aged between postnatal day P(0) and P(2) were used throughout. All 
research involving animals was approved by the University of Cambridge Ethics Committee 
and by the Home Office of the United Kingdom under the Animals Scientific Procedures Act, 
1986. Rat pups were decapitated after lethal injection of benzodiazepines; forebrains were 
exposed and then transferred to sterilin plate with dissection Media. Under dissecting 
microscope, using curved forceps, two hemispheres were severed, and meninges were 
removed. The hindbrain/midbrain and olfactory bulbs were removed, so only the cortex was 
left. The cortices were transferred into 5ml universal tube containing 4ml of dissection Media 
which was kept on ice. Tissues were cut thoroughly with scissors by rotating the vial and 
chopping with scissors. Filtered dissociation solution (1ml/pup) was added into vial of mince 
cortices and then incubated for 1 hr at 37°C. After 1 hr, supernatant was gently removed and 
1ml of ovomucoid solution was added to stop papain digestion. The final volume for the 
centrifuge was made up to 8ml with mixed glia culture media to allow the pellet to be clearly 
visible after centrifugation. Tissue volume was then centrifuged for 8 min at 1000rpm. After 
aspiration of the supernatant, pellet was resuspended with 1ml of MGM and triturated 
vigorously. Volume was brought to a final of 1.5 pup cortices/ ml. Resuspended digested 
cortices were added to each T-75 flask, which was previously coated with Poly-D-Lysine 
(PDL) (Sigma). Culture media was changed in every 2–3 days for ~10 days. OPCs were ready 
for mechanical dissociation after 10-12 days. Each pup was usually expected to yield ~ 1 
million OPCs. 
The caps of the T-75 flasks containing mixed glia were wrapped with parafilm to ensure no 
gas exchange. The sealed flasks were then placed onto the universal platform of the orbital 
shaker and shaked for 1 hour at 195 rpm at 37°C. After the hour, the medium was aspirated 
and replaced with pre-equilibrated mixed glia media and resumed shaking overnight for ~16 
hours at the same speed. This shaking allows microglia and OPCs to detach and remain in cell 
suspension. After the long shaking, cell suspension was transferred to 10 cm sterilin non-
treated plastic dishes and incubated for 30 minutes. This process removes microglia as they 
attach to plastic quickly; OPCs remain in the cell suspension. Media was then removed from 
dishes and centrifuged for 8 min at 1000 rpm. 1ml of OPC culture medium was added to dilute 
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cell pellet. 10µl of diluted OPCs was taken to count the OPCs number using haemocytometer. 
Cells were then resuspended in the appropriate volume and plated on PDL coated 
























2.2.6 OPCs isolation using magnetic activated cell sorting (MACS) method 
Neonatal (P5-P7) rats were decapitated after lethal injection of benzodiazepines. Brains were 
removed shortly after death (including cerebrum and cerebellum) and placed into ice cold 
HALF isolation medium (Hibernate A Low Fluorescence), supplemented with 2% of B27. 
Meninges, olfactory bulbs were removed from brain and chopped mechanically into pieces 
(~1mm) using sterile scalps. The tissue was then spin down in 100g for 2 min in room 
temperature (RT) and then suspended in dissociation solution for 30 min in 37°C on a shaker 
set to 55 RPM. Papain digestion was stopped through addition of HBSS (Gibco). The tissue 
was then centrifuged for 5 min in 250g. Supernatant was aspirated followed by resuspension 
in trituration solution for 5 min in RT. 
To obtain single cell suspension the tissue suspension was triturated 10 times using a 5ml 
serological pipette followed by further 3 times trituration with fire polished glass pipettes 
(opening diameter > 0.5mm). After each trituration step the suspension was allowed to 
sediment (~1-2 min) and the supernatant was transferred into a fresh tube. 2ml of fresh 
trituration solution were added after each trituration step. Supernatant was then filtered through 
70mm cell strainers to remove undigested tissue bits. 90% isotonic percoll (GE Healthcare, 17-
0891-01, in 10xPBS pH7.2 (Gibco) was added to the filtered suspension. Final percoll 
concentration of 22.5% was achieved by adding phenol-red free DMEM/F12 (Gibco). Cell 
suspension was centrifuged for 20 min in 800g which resultant separation of debris and cells. 
Cells containing pellet was then exposed to red blood cell (RBC) lysis buffer (Sigma-Aldrich) 
in order to remove contaminating red blood cells. 
After that 10ml of HBSS was added and centrifuged for 5 min in 300g. The cell pellet was 
resuspended in 0.5ml MWB supplemented with 10ng/ml human recombinant insulin (Gibco). 
Then 2.5mg of mouse-anti-rat-A2B5-IgM antibody (Millipore) was added for every 10 million 
cells, incubated for 15 min, kept on a slow rotating shaker at 4°C. The tube was then fill with 
7ml of MWB and centrifuged for 5 min at 300g. The pellet as then resuspend in 80ml of MWB 
supplemented with 20ml of rat-anti-mouse-IgM antibody (Milteny), incubated for 10 min, kept 
on a slow rotating shaker at 4°C. After that, 7ml MWB was added and centrifuged for 5 min at 
300g to wash out secondary antibody residue. The cell pellet was resuspended in 0.5ml and 
MACS was performed according to the recommendations of the supplier. Briefly, a MS column 
(Milteny) were inserted into Mini MACS Separator (Miltenyi) and pre-wet with 0.5ml MWB. 
Resuspended cells were put onto one MS column. Subsequently the column was washed three 
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times using 500µl MWB for each wash. Finally, A2B5 positive cells were flushed out the 
























Rat (P5-7) brain tissue dissociated 
into a single cell suspension.
Incubation of Ms anti-A2B5 antibody 


















Elution of positive 
selection of OPCs.
OPCs
Figure 2.1 Schematic presentation of OPCs isolation procedure using MACS. 
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2.2.7 Culture of OPCs 
A day before the cell dissociation and isolation, cover slips were prepared. 13mm cover slips 
were first dipped into ethanol to avoid contamination. Each of the cover slips was then placed 
in a 24 well plate and left resting against the side of the well to dry out. Both coverslips and 
petri-dishes were coated with PDL for ~1 hour at 37°C, 5 % CO2 in an incubator followed by 
washed out with distilled water. After isolation of OPCs, cells were plated on PDL coated 
plates/coverslips according to table 2.4. Approximately 30,000 cells per well in 24 well plate 
and 100,000 cells per 23mm petri-dish were plated onto the centre of each pre-prepared cover 
slip and dishes. Isolated OPCs were cultured at 37°C in 5% CO2 in OPCs medium.  
The medium was completely exchanged to OPC medium with 10ng/ml bFGF and PDGF-AA 
after overnight culture to remove any dead cells. A high proportion of OPCs within the cell 
culture were maintained by daily addition of 10ng/ml PDGF-AA and 10ng/ml bFGF. 
Oligodendrocytes (OLGs) were generated by growing cells in OPCs in medium supplemented 
with 40ng/ml T3 for 4 day in vitro (DIV). During differentiation or proliferation experiments 
70% of the medium were replaced every 48h and growth factors, T3 or other small molecules 
were added fresh to the culture. The culture medium used was 500ml for cultures in 24 well 
plate wells and 2ml for cultures in 10mm glass bottom petri-dishes.  
 











Cell number Culture Plate Surface area 
1.27x106 T-75 7500mm2 
423,729 T-25 2500 mm2 
163,050 6 well 962 mm2 
30,000 24 well 177 mm2 
6,505 96 well 38.4 mm2 
53,220 20mm cover slip 314 mm2 




OPCs and OLGs from different DIV in culture were considered for immunostaining. Cell 
media was carefully aspirated from the wells. The cells were fixed with 4 % paraformaldehyde 
(PFA) and incubated for 10 min at room temperature. PFA was removed and the cells were 
washed two times for 10 min in PBS. 
Blocking 
The blocking solution was prepared with 5% normal goat serum in PBS for cell surface 
antigens and in PBS with 0.1 % triton (PBS-T) for non-surface antigens. Solution (~100µl) 
was added to each well and incubated for 1h at room temperature in the dark. 
Primary antibodies 
The cells were incubated overnight in the dark at 4°C with primary antibodies in 5 % NGS in 
PBS-T solution. 
Secondary antibodies 
The following day, the cells were washed three times for 10 min in PBS to remove all 
unlabelled primary antibodies. The cells were then incubated for 1h in the dark at RT with 
secondary antibodies in 5% NGS in PBS-T solution. After the incubation with secondary 
antibodies, the cells were washed two times for 10 min in PBS. Cells were then treated with 
DAPI (1:1000 in PBS) for 5 minutes and washed two times for 10 min in PBS 
Mounting 
Approximately 10µl of mounting media was added onto a glass slide. The cover slip with cells 
was then carefully taken from the well and placed onto the mounting media with the cells facing 
down. Slides were left to dry and stored at 4 °C. 
Confocal microscopy 
All cell images were captured with Leica SP5 confocal laser scanning microscope system and 





2.2.9 Single cell Ca2+ imaging 
To measure Ca2+ signalling, cells were seeded in 10mm glass bottom dishes and used when 
cells were ~90% confluent. Since human jurkat T cells were non-adherent therefore these cells 
were seeded on a PDL coated petri-dhishes. OPCs were also grown in PDL coated dish due to 
their less-adherent characteristics. All other cells like, RBL-1, SHSY-5Y, and lung cancer cells 
used for Ca2+ imaging were adherent therefore no coating required. 
Fura-2 acetoxymethyl (AM) was dissolved in 20% Pluronic® F-127 solution in DMSO to 2mM 
stock concentration. The cells were thoroughly washed several times using pre-warmed HBSS 
buffer. The pH was maintained at 7.4. Special care was taken while handling the cells, as they 
could easily detached from the dishes. All the cells were loaded with 1µM fura-2/AM except 
OPCs that required 4µM, in HBSS++ for 40min at room temperature in the dark chamber. The 
Fura-2/AM ester is an uncharged ester and as such is spontaneously taken up by the cells. Once 
within the cell, endogenous non-specific esterase cleaves off the AM group and free fura-2 
becomes trapped inside the cell because of being charged. Fura-2 is sensitive to Ca2+ due to 
presence of carboxyl groups. Finally, the cells were washed in fresh pre-warmed buffer to 
remove the dye from the medium and transferred to fresh supplemented HBSS buffer for 30min 
to ensure the de-esterification of all the dye inside the cells. All the experiments were carried 
out at room temperature. The calcium concentration in the buffer was 1.25mM as indicated by 
the provider, which lies in the physiological range for extracellular calcium. This procedure 
has been adopted after trying several fura-2/AM concentrations and different loading times at 
37°C or at room temperature. It has been reported that 37°C can favour the 
compartmentalization of the dye in several organelles, removing the de-esterified dye from the 
cytosol. Inspecting the spatial distribution of the indicator is usually enough to diagnose any 
uneven loading of the dye.  
In this work, several experiments were performed from where [Ca2+]i response was determined 
by different stimulus including 100µM Carbachol (CCh), 2µM Tg, 40ng/ml PDGF-AA, 70mM 
KCl and 100µM OAG. CCh, Tg, and OAG were dissolved in DMSO whereas PDGF-AA and 
KCl were diluted in deionized water. To quantify store Ca2+ depletion and Ca2+ entry from 
stimulus, responses were calculated from calibrated traces using MetaFluor® Fluorescence 
Ratio Imaging Software (Molecular Devices, USA). Ca2+ add-back experiments (Bird et al. 
2008) were performed when it was required to measure both intracellular Ca2+ release as well 
as extracellular Ca2+ entry. Fura-2 fluorescence was monitored continuously using excitation 
wavelength of 355nm and 380nm, respectively.  
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The typical experimental design was as follows: baseline fluorescence was captured for >50s, 
after which stimulus were added. The calcium response to the applied stimulus was followed 
for ~15 min, and then a fluorescence calibration was performed in situ. 10µM ionomycin 
(Cayman Chemical, USA) and 1mM MnCl2 were added to the buffer ~5min before finishing 
the experiment to determine auto-fluorescence.  
Image acquisition and analysis 
Fluorescence images were captured using a Nikon Eclipse Ti-S Microscope mounted with a 
QImaging QIClick digital CCD camera and using a 10X (NA 0.25) air objective. Excitation 
was provided by a Dual OptoLED Power Supply (Cairn), alternating between both 355nm and 
380nm wavelength LEDs. Both LEDs have a 10nm spectral bandwidth, i.e., the full width of 
the emitted spectra at half-maximum intensity. Emission fluorescence of the fura-2 signal was 
collected at 510nm (470nm–550nm). 12-bit images were acquired every 5 seconds with 
MetaFluor® (Molecular Devices, USA). The fluorescence at each time-point was extracted for 
both 355nm and 380nm wavelengths, corrected for autofluorescence and the 355nm/380nm 















2.2.10 Evaluation of cytotoxicity for OPCs 
Cell death was assessed by propidium iodide staining as per the method previously published 
by Lecoeur 2002. Briefly, OPCs were first chronically treated with drugs, compounds or 
vehicle. Afterwards, cells were incubated with 10µg/ml propidium iodide for 20 min at 37°C. 
Cells were then washed with PBS and fixed for 15 min with 100% ice cold methanol at -20°C. 
Cells within each treatment group were later imaged using confocal microscopy with the 20x 
objective. 
 
2.2.11 Statistical analysis 
Results were expressed as means ± SEM for n independent experiments, with each experiment 
performed minimally in triplicate. The latter in this study involved Ca2+ imaging of drug-
treated cells in at least three different days (3 petri-dish of cells per drug per day) done with 
paired control group (3 petri-dishes of cells per day). Statistical comparisons of mean values 
were performed using GraphPad Prism 5 (GraphPad software Inc., CA, USA). One-way 
ANOVA followed by Dunnett’s test was used to compare among groups. Data for the two 
groups were compared using the unpaired two-tailed Student’s t-test. The level of significance 






































3.1 Results  
3.1.1 Ligand-based virtual screening and identification of hits for bioassay 
Several well-known SOCE inhibitors were used as 3D baits (Fig.3.1) to virtually screen a 
conformer library of approved drugs namely the eDrug3D database  (Pihan et al. 2012) using 
ROCS (Open Eye Scientific) (Naylor et.al. 2019). Initial ranking of the hits was based on the 
Tanimoto Combo (TC) score which is a linear sum of the shape tanimoto and colour tanimoto 
score.  First 300 hits obtained this way were then re-ranked on the basis of electrostatics 
tanimoto combo (ET_combo) score using EON. 
After visual inspection of each hit for electrostatic similarity (Fig. 3.2) and considering their 
ranks in ROCS and EON based outputs, total of 10 drugs were purchased for the study. 
















Figure 3.1 2D and 3D representations of the bait molecules.  
2D representations of the bait molecules and their corresponding 3D queries used in the 
ligand-based virtual screening. The 3D queries were generated using EON (version 
3.2.1.4, OpenEye Scientific Software, Santa Fe, NM). 
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Figure 3.2 2D and 3D representations of drug molecules.  
2D representations of the drug molecules and their corresponding 3D queries used in the 
ligand-based virtual screening. The 3D queries were generated using EON (version 3.2.1.4, 
OpenEye Scientific Software, Santa Fe, NM). 
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Table 3.1 Primary list of drugs tested for their ability to inhibit SOCE 
 
Table 3.1 summarizes list of drugs those were chosen on the basis of several aspects including 
visual inspection using VIDA, their similarities in electrostatic isopotential contour surfaces 
(EON-genrated) with the cognate bait, their TC score and ET_PB score, their rank and 
frequency of appearing within top 100 hits in ROCS as well as EON based screening.  
Of the 10 chosen drugs, leflunomide and its pro-drug teriflunomide are known to inhibit de 
novo pyrimidine biosynthesis by acting on dihydroorotate dehydrogenase (DHODH) (Yara and 
Bidin 2015). Tolvaptan and conivaptan are effective non-peptide antagonists for the arginine 





Similarity indices of the tested drugs with the cognate query compounds 
 
































Leflunomide 1(1.301) 1 
(1.239) 




Teriflunomide 48 (0.897) 5 
(1.036) 
14 (0.973) 10 (1.016) 9(1.003) 7 (1.131)  266 
(0.541) 
Tolvaptan 10 (0.973) 20 
(0.925) 














Omeprazole 32(0.913) 42 
(0.853) 
70(0.882) 4 (1.0860) 33 
(0.945) 
22 (1.002) 2 (1.087) 1 (1.3) 
Lansoprazole 50 (0.895) 72 
(0.805) 
49(0.901) 291(0.667) 358 
(0.811) 
- 21 (1.01) 7 
(1.034) 






19 (1.03)   










Terazosin 27 (0.915) 7 
(1.015) 
39(0.918) 7 (1.0420) 10 
(1.002) 
3 (1.189) 9 (1.041) 13 
(1.011) 











gastric proton pump inhibitors (Shin and Kim 2013) and roflumilast is a selective inhibitor of 
phosphodiesterase isoform 4 (PDE4) (Rabe 2011).  
Prazosin and terazosin are acting as alpha-1 adrenergic receptor blockers (Tsujii 2000). 
Rufinamide is a novel FDA approved anticonvulsant medication, some evidences showed this 























3.1.2 Investigation of the effects of the selected hits on SOCE 
Single cell Ca2+ imaging experiments with rat basophilic leukemia-1 (RBL-1) cells and human 
SHSY-5Y neuroblastoma cells (Fig. 3.3) were used (Bird et al. 2008) for evaluating the 
performance of the purchased drugs as SOCE modulator. This is a widely-used approach for 









RBL cells were developed in 1973 by inducing leukemia in rats fed with the chemical 
carcinogen, β-chlorethylamine (Eccleston et al. 1973). RBL-1 cells expressed the high affinity 
receptor for immunoglobulin E (FcɛRI) and displayed mast cell characteristics (Siraganian and 
Hook 1975). This cell is widely used for the identification of the causative agent of an 
individual's allergic response (Wilson et al. 1993) as well as for studying SOCE pathway using 
microscopy and electrophysiology technique (i.e ICRAC) (Bakowski et al.2001; Fasolato et al. 
1998; Fierro and Parekh 1999; Huang and Putney 1998; Parekh et al. 1997). 
SHSY-5Y neuroblastoma cells were first derived from cells of the neural crest (Goodman et 
al. 1985). The SK-N-SH neuroblastoma cell line was established in 1970 from a bone marrow 
aspiration of a 4 year old female with metastatic neuroblastoma (Biedler et al. 1973) . The SK-
N-SH cell line is comprised of N- and S-type cells. It has three clone including SH-SY, SH-
SY5, and SH-SY5Y. Predominately composed of N-type cells, the SH-SY5Y cell line remains 
heterogeneous in nature as N-type cells are able to give rise to S-type cells (Ross et al. 1983). 
This cell line has been extensively utilized for studying neuronal differentiation, as model for 
neurodegenerative diseases as well as for Ca2+ signalling pathways.  
 
Figure 3.3 Bright field images of cells used for single cell Ca2+ imaging. 
(a) RBL-1 cells and (b) SHSY-5Y cells. 
a b 
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The latter can be triggered in these cells by either stimulating Gq coupled receptors (e.g. 
muscarinic receptors, purinergic P2Ys, vasopressin receptors etc.) using suitable agonists or 
depolarisation of the plasma membrane using high concentration of salt such as KCl (Vaughan 























3.1.2.1 Evaluation of the effects of chosen drugs on SOCE in RBL-1 cells  
Extracellular Ca2+ entry inhibition by the higher dose of drug was observed in RBL-1 cells 
loaded with 2µM fura-2/AM, stimulated by 2µM thapsigargin (Tg). Tg irreversibly inhibits the 
sarco-endoplasmic reticulum Ca2+ ATPase dependent pumps (SERCAs) (Lytton et al. 1991) 
which then allows passive depletion of the ER Ca2+ store leading to the triggering of  SOCE 
(Pozzan et al. 1994; Putney 2009). Cells were pre-incubated 100µM of each drug for ~15min. 
Control cells were pre-incubated with 0.01% DMSO. With the application of 2µM Tg in 
absence of any extracellular Ca2+, [Ca2+]i increased substantially and typically peaked within 
100s of application and then slowly declined towards the baseline within 400-500s. At that 
point addition of 2mM CaCl2 extracellularly triggered the entry of extracellular Ca2+ into the 
cytosol (Fig. 3.4). The drugs were first screened at 100µM and at this concentration most of 
the purchased drugs showed substantial (by ≥60%) suppression of SOCE. When compared to 
the control group, 7 out of 10 drugs at 100µM caused substantial and statistically significant 
(P<0.001) decrease in the fluorescence ratio corresponding to the Ca2+ entry phase (Fig. 3.4). 
Among all, tolvaptan and teriflunomide appeared to manifest the maximum suppression of the 
Ca2+ entry. Only prazosin, terazosin and rufinamide had no effect on SOCE at this high 






























































































































































































































































































































































































100 µM 100 µM
30 µM 30 µM
10 µM 10 µM
03 µM 03 µM
Figure 3.4 Effects of chosen drugs on the SOCE in RBL-1. Histograms (left column) 
showing the highest peak SOCE levels triggered by Tg (2µM) in control cells and cells pre-
treated with each drug at different doses (µM). Sample traces (right column) representing 
Ca2+ signals (indicated by fura-2 fluorescence ratio) triggered by adding Tg to cells with or 
without pre-treatment of the chosen drugs (shown in various coloured lines). Each value 
(mean ± SEM) was derived from 3-5 independent experiments done in different days with 




Subsequently the remaining drugs were tested at progressively lower doses; the lowest 
concentration at which all seven drugs except omeprazole and conivaptan, retained their ability 
to inhibit SOCE significantly was 10µM (Fig. 3.4).  
 
3.1.2.2 Concentration-response studies to determine IC50 for selected drugs 
For those 5 drugs which significantly suppressed SOCE at 10µM, complete concentration-
response studies were carried out with a view to evaluating the concentration-dependence of 
their action as well as determining the half-maximal inhibitory concentration (IC50) for each 
drug. As can be seen in Fig. 3.5, all 5 drugs as well as the positive control, BTP2 showed dose-
dependent suppression of SOCE over the concentration range of 300µM to 3µM. At 
concentration below 3µM, none of the drugs under the standard experimental protocol (~20 
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Figure 3.5 Dose response curves (DRCs) for selected drugs. 
DRCs demonstrating the dose-dependence of inhibitory effect of indicated drugs 
and BTP2 at µM dose on the SOCE in RBL-1 cells triggered by Tg. Each value 















































































3.1.2.3 Evaluating the drugs in SHSY-5Y neuroblastoma cells 
In order to know whether the observed effect of the five drugs on SOCE was cell-type specific 
or not, those 5 drugs then screened at 10µM dose against SOCE also in SHSY-5Y cells (a 
human neuroblastoma cell line) using the same protocol that used for the RBL-1 cells. As can 
be seen in Fig. 3.6, all those drugs retained their ability to suppress SOCE significantly in 
























Figure 3.6 Best performing drugs on the SOCE in SHSY-5Y cells.  
(a) Histograms showing the highest peak SOCE levels triggered by Tg in control cells and 
cells pre-treated with each drug at 10µM. (b) Sample traces representing Ca2+ in cells with 
or without pre-treatment of the chosen drugs. Each value (mean ± SEM) was derived from 
3-5 independent experiments done in different days with 30-60 cells. One-way ANOVA 
















































































Figure 3.7 The chosen drugs on SOCE of RBL-1 cells following prolonged treatment.  
(a) Histograms showing the peak SOCE levels triggered by Tg in control cells and cells pre-
treated with each drug at 1µM dose for 48 hrs. (b) Sample traces representing Ca2+ in cells 
with or without pre-treatment of the chosen drugs. Each value (mean ± SEM) was derived 
from 3-5 independent experiments done in different days with 50-70 cells. One-way ANOVA 
followed by Dunnett’s test was used for statistical comparison. 
 
3.1.2.4 SOCE inhibitory properties of the drugs after prolonged treatment 
To evaluate whether longer incubation of the cells with these drugs could improve their potency 
for SOCE suppression, RBL-1H cells were pre-treated with 1µM of the selected drugs and 
SOCE was recorded after 48 hours. As can be seen in Fig. 3.7, significantly inhibition of SOCE 


























3.1.2.5 Instantaneous effect of the drugs on SOCE inhibition in RBL-1 cells 
In most of the single cell Ca2+ imaging experiments mentioned above, cells were exposed to 
drugs for ~15 minutes which was a sort of semi-acute challenge. In order to evaluate whether 
the drugs could affect SOCE if added in a more acute way, these drugs were added at a final 
concentration of 50µM to the bath solution (containing no Ca2+) to just 5-10s prior to the Ca2+ 
addition. It turned out that 3 drugs namely leflunomide, teriflunomide and tolvaptan, could 
























Figure 3.8 Instantaneous effect of the chosen drugs on SOCE in RBL-1 cells.  
(a) Histograms showing the peak SOCE levels triggered by Tg in control cells and cells super-
acutely exposed to each drug at 50µM dose. (b) Sample traces representing Ca2+ in cells with 
or without super-acute treatment of the chosen drugs. Each value (mean ± SEM) was derived 
from 3-5 independent experiments done in different days with 50-80 cells. One-way ANOVA 

















































































3.1.2.6 Drugs on transient receptor potential channel C (TRPC) mediated Ca2+ entry 
Next, it was investigated whether the drugs that suppressed SOCE, could affect Ca2+ entry in 
RBL-1 cells in response addition of 1-oleoyl-2-acetyl-sn-glycerol (OAG). The latter is a 
membrane permeable, synthetic analogue of diacylglycerol (DAG) and is well known to 
activate members of the TRPC family of ion channels including TRPC3, TRPC6 and TRPC7 
(Hofmann et al. 1999). As can been seen in Fig. 3.9, OAG at 150µM did trigger Ca2+ signal 
only in presence of extracellular Ca2+ in RBL-1 cells. Among the tested drugs at 10µM dose, 
only leflunomide and teriflunomide showed significant inhibition of the OAG-evoked Ca2+ 





































































































Figure 3.9 Effect of the drugs on TRPC channel mediated Ca2+ entry in RBL-1 cells.  
(a) Histograms showing the peak OAG-activated Ca2+ entry in control cells and cells treated 
with 10µM of each drug. (b) Sample traces representing Ca2+ signals triggered by adding 
150µM of OAG to RBL-1 cells with or without pre-treatment of the chosen drugs. Each value 
(mean ± SEM) was derived from 3-5 independent experiments done in different days with 30-
80 cells. One-way ANOVA followed by Dunnett’s test was used for statistical comparison. 
 50 
3.1.2.7 Effects of selected drugs on nuclear translocation of NFAT 
To determine whether the chosen drugs could affect SOCE-dependent cell signalling and 
relevant biological responses in intact cells, their effect was evaluated on the nuclear 
translocation of the nuclear factor of activated T cells (NFAT). HeLa cells stably expressing 
NFAT1 (1-460)-GFP (Gwack et al. 2006) was used for this. As can be observed in Fig. 3.10, 
ionomycin treatment (1µM for 40 min) significantly increased the nuclear translocation of 
NFAT1 (1-460)-GFP in the control group but such increase was not observed for cells treated 




















Figure 3.10 Effects of the drugs on nuclear translocation of NFAT.  
(a) Representative confocal images of HeLa cells showing subcellular localisation of NFAT 
(1–460)-GFP following application of ionomycin (1µM for 40 min) preceded by pre-
treatment with the chosen drugs (20µM) and BTP2 (10µM) for 30 min. The basal and control 
groups received only DMSO pre-treatment and no ionomycin was added to the basal group 
subsequently. (b) Bar graphs showing the nucleus to cytoplasm ratio (mean ± SEM, n= 3 
independent days, 12-15 cells for each condition) for the NFAT (1-460)-GFP under various 































basal (no ionomycin) control BTP2 


























































3.1.2.8 Effects of chosen drugs on the oligomerisation of STIM1 and Orai1 
With a view to gaining some insight into the possible mechanism underlying the SOCE-
inhibitor property of those 5 drugs, the effects of the drugs were then evaluated on the clustering 
of STIM1 and also of Orai1, using confocal microscopy with a HEK293 cell line with an 
inducible mCherry-STIM1-T2A-Orai1-eGFP (Sadaghiani et al. 2014). Qualitative and 
quantitative assessment showed there was no significant change in the punctuate distribution 
of mCherry-STIM1 or Orai1-eGFP in presence and absence of any of the 5 drugs and BTP2, 













































































































































Figure 3.11 Effects of the drugs on clustering of STIM-1 and Orai-1 protein.  
(a) Representative images of HEK293 cells co-expressing mCherry-STIM1 (red) and Orai1-
eGFP (green) showing translocation and colocalization of both proteins in characteristic 
puncta after treatment with Tg, no Tg and drugs (images shown in next page). Quantification 
of mCherry-Stim1 (b) and GFP-Orai1 (c) puncta formation. The number of puncta were 
determined using ImageJ software and were expressed as mean/µm2 of area ± SEM. Each bar 
represents data from 15-18 cells from 3 different experiments. One-way ANOVA followed by 


























































































Figure 3.11a Effects of the drugs on clustering of STIM1 and Orai1 protein. 
(a) Representative images of HEK293 cells co-expressing mCherry-STIM1 (red) 
and Orai1-eGFP (green) showing translocation and colocalization of both proteins 







There are quite a few small molecule inhibitors of SOCE available. 2-APB, BTP2 (also known 
as YM-58483 or Pyr2), Pyr6, Synta 66 and AnCoA4 are the most potential SOCE inhibitors 
(Sweeney et al. 2009; Anant B. Parekh 2010; Jairaman and Prakriya 2013; Tian et al. 2016).  
Structures of some widely-used SOCE inhibitors namely BTP2, Pyr6, Synta66 and AnCoA4 
were exploited as baits and sought out to find whether members of the existing drugs share any 
significant similarity in 3D shape and surface electrostatics with these baits and if so, whether 
those drugs could phenocopy the known SOCE inhibitors in suppressing SOCE. The overall 
underlying principle stems from the notion that ligands with similar 3D shape and electrostatic 
properties are likely to bind to the similar binding pocket on target proteins and thus are likely 
to manifest similar pharmacological properties (Naylor et al. 2009, and Vasudevan et. a. 2012). 
Following completion of ligand-based virtual screening, 10 drug molecules were shortlisted. 
Following ~15min pre-incubation, of the 10 drug molecules and compounds purchased, 07 
drugs and compound caused significant suppression of SOCE when used at 100µM (Fig. 3.4) 
in RBL-1 cells. Drugs pre-incubated at progressively lower doses (30µM, 10µM, and 3µM 
respectively), only three of these drugs namely leflunomide, teriflunomide and tolvaptan 
retained their ability for SOCE inhibition in RBL-1 cell lines but none of these drugs had any 
effect on SOCE at 3µM (Fig. 3.4). Complete concentration-response studies for the 5 drugs as 
well as the positive control, BTP2 were carried out in RBl-1 cells to evaluate the concentration-
dependence of their action as well as determining the IC50 for each drug. Of these 5 drugs, 
roflumilast was the most potent SOCE inhibitor drug with lowest IC50 dose (~4.5µM) (Fig. 
3.5). BTP2 blocked SOCE in RBL-1 cell with IC50 of ~4.4µM which is way higher than 
previously reported IC50 dose (0.1-0.3µM) in HEK293 cells, DT40 B cells, and A7r5 smooth 
muscle cells (He et al. 2005). This indicated IC50 dose might vary depending on cell types. 
Drugs also retained their ability to inhibit SOCE in SHSY-5Y cells, indicating that the observed 
effect was not cell type specific (Fig. 3.6). Chronic incubation (~24hrs) at lesser dose (1µM), 





Study showed SOCE channels not only form heteromeric complex with Orai proteins but also 
with TRPCs (Liao et al. 2008), therefore checking any effect of these drugs on TRPCC 
mediated Ca2+ entry was also considered. Of these drugs, only leflunomide and teriflunomide 
could significantly inhibit Ca2+ signals mediated by TRPC channels (Fig. 3.9), although other 
3 drugs did not supress such entry, the former can be justified as 2-APB, another known SOCE 
inhibitor, is widely known to block TRPC and therefore, ROCE (Lievremont et al. 2005).  
It is interesting to note that the concentrations used in the present study were perhaps achievable 
physiologically, given what is known about the pharmacokinetics of these drugs (table 3.2).  
SOCE mediated Ca2+ signals are critical for the calmodulin-dependent activation of the 
phosphatase calcineurin in lymphocyte and relevant cell lines including RBL-1 cells. 
Calcineurin in these cells then dephosphorylates and thus promotes the nuclear translocation 
of NFAT isoforms. NFAT translocation into nucleus can be disrupted by inhibition of SOCE, 
which usually happens due to either structural defect in the underlying proteins (for e.g. R91W 
mutation in CRAC channel pore) or presence of SOCE blockers. Identification of SOCE 
modulators or evaluation of the consequences of attenuated SOCE in intact cells can be studied 
using fluorescence-tagged NFAT (Prakriya and Lewis 2015). 
Given the observed SOCE-inhibitory property of the chosen drugs, it was satisfying to see their 
complementary ability to retard nuclear translocation of NFAT1(1-460)-GFP in HeLa cells 
(Fig. 3.10). Although leflunomide was qualitatively looking similar to other drugs however, 
upon quantitative assessment, was proven to be not affecting the nucleus to cytoplasm ratio of 
NFAT1(1-460)-GFP, significantly (Fig. 3.10). Whether this was a genuine property of 
leflunomide or a contribution from a contradictory off-target effect, requires further 
investigation.  
Cells were incubated with drugs acutely (~20min) prior to the Ca2+ imaging experiment. This 
was probably enough time for the drugs action against STIM1 oligomerisation and/or STIM1-
Orai1 coupling that are critical for SOCE activation. Drugs were applied super acutely (~10 
sec before Ca2+ add-back) during imaging to know whether the drugs could affect SOCE upon 
more acute challenge which could at least indicate whether they could inhibit SOCE when 
Orai1 was already activated, presumably through interaction with aggregated STIM1 proteins.  
Leflunomide, teriflunomide and tolvaptan retained their ability to inhibit SOCE in super acute 
experiment (Fig 3.8). Surprisingly BTP2, known SOCE inhibitor, and two other drugs, 
roflumilast and lansoprazole, did not affect SOCE under such experimental setup. This could 
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be due to lower degree of lipid solubility of the drugs and compound which may delay the 
diffusion (Cerpnjak et al. 2013). 
Previous studies reported SOCE inhibition by BTP2 depends on cell types and duration of 
treatment (Ishikawa et al. 2003; Zitt et al. 2004; He et al. 2005). For example, Ishikawa et al. 
indicated BTP2 was equally effective on SOCE inhibition in Jurkat T cells regardless of acute 
or chronic treatment. Although in another study led by Zitt et al. have shown, BTP2 only 
affected SOCE substantially in Jurkat T cells when the cells were preincubated with the 
compound at least for 2 hrs or more. On the other hand, according to He et al. 2005, BTP2 
potentially inhibited SOCE in HEK-293 cells, DT40 cells and A7r5 cells within 10 min of 
incubation. So, variability in BTP2 mediated SOCE inhibition and related molecules appeared 
to be credible depending on cell types and/or treatment duration. However, the reasons for such 
variation remain obscure.  
The matter of fact that leflunomide, teriflunomide and tolvaptan could block SOCE entry even 
at acute application which was intriguing. This implied that these drugs could act either on 
Orai1 channels that were already activated due Tg triggered ER store depletion via interaction 
with aggregated STIM1 proteins or these drugs may block SOCE extracellularly. Immediate 
cell permeability of these drugs may also be another possible mode of action mechanism in 
case if they worked intracellularly. Although in acute challenge, roflumilast and lansoprazole 
did not inhibit SOCE, it was difficult to be definitive about their lack of effect on STIM1 
oligomerisation and/or coupling of STIM1-Orai1. This can be said because the known SOCE 
blocker, BTP2, had no effect on STIM1 puncta formation either and also wasn’t effective in 
acute challenge experiment. Therefore, experiments were executed to see the effects of the 
drugs on the clustering of STIM1 and also of Orai1, using confocal microscopy with a HEK293 
cell line with an inducible mCherry-STIM1-T2A-Orai1-eGFP. None of the drugs along with 
BTP2 showed any efficiency on either STIM1 puncta formation or Orai1 puncta formation 
(Fig 3.11). Studies already have shown that BTP2 neither affected STIM1 puncta formation 
nor STIM1-Orai1 coupling (Jairaman and Prakriya 2013) and thus its SOCE-inhibitory 
properties were attributed to its possible extracellular action, for example, acting as pore 
blocker. This may be true because it was also found that SOCE channel inhibition mediated by 
BTP2 was affected by the external Ca2+ concentration; higher external Ca2+ concentrations 
were correlated with reduced inhibitory effect on the SOCE channel (Zitt et al. 2004). Another 
presumable BTP2 action site on SOCE inhibition could be the drebin, an actin reorganizing 
protein, that was identified as a potential binding site of BTP2 (Zanto et al. 2011). Drebrin may 
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play a role in regulating SOCE by affecting the actin cytoskeleton, although its already been 
reported that actin cytoskeleton has not any significant role to play in SOCE (Ribeiro, Reece, 
and Putney 1997).  
Given the significant similarities of the drugs with the baits, particularly, BTP2, used in this 
study and the observation that they did not interfere neither with STIM1 puncta nor with 
STIM1-Orai1 complex formation (Fig 3.11), it can be hypothesized that these agents inhibited 
SOCE probably via pore blocking at extracellular site or other extracellular binding sites, for 
instance, on dbrein protein. This requires direct experimental validation in future. 
Out of the best performing drugs, leflunomide and its active metabolite, teriflunomide were 
ranked the top in both ROCS and EON-based ranks of the hits obtained from screening with 
the known SOCE blockers, those were considered as baits in this study. Leflunomide is a pro-
drug and ~70% of the orally-administered leflunomide rapidly undergoes opening of the 
isoxazole ring to produce the active malononitrilamide metabolite teriflunomide (Yara and 
Bidin 2015). Both these drugs have been clinically used as orally-active, disease-modifying 
immunosuppressive drugs for treating autoimmune type-inflammatory diseases like rheumatic 
arthritis (RA), and multiple sclerosis (MS). 
Leflunomide (Arava) was first approved and licensed for the treatment of RA in 1998. Later 
on, teriflunomide (Aubagio) was synthesised, approved and licensed for the treatment of MS 
in 2012. The only known mechanism of action of these drugs involve the inhibition of de novo 
pyrimidine biosynthesis by acting on the mitochondrial enzyme dihydroorotate dehydrogenase 
(DHODH)- an enzyme expressed at high levels in proliferating lymphocytes. This results in 
blockade of de novo pyrimidine biosynthesis and reduction of activated lymphocytes 
proliferation, therefore it has also been used as an immunosuppressive drug (Yara and Bidin 
2015). However, teriflunomide intake might cause other cellular effects which can be 
independent of DHODH inhibition mechanism. These cellular effects include lowering the 
cytokine production, cell surface molecules expression as well as cellular migration (Korn et 
al. 2004). Therefore, it can be said that alongside the ability to inhibit lymphocyte proliferation 





Table 3.2 Drugs with their doses and maximum plasma concentrations (Cmax) 





Roflumilast 250-500mg ~1-nM (Rabe 2011) 
Lansoprazole 10-30mg ~3.5µM (Shin and Kim 2013) 
Tolvaptan 30mg ~0.9-1µM (Shoaf et al. 2014) 
Teriflunomide 7-14mg ~72-168µM (Oh and O’Connor 2014)  
Table 3.2 demonstrates that the concentrations used in the present study were perhaps 
achievable physiologically, given what is known about the pharmacokinetics of these drugs. 
Hitherto it is known that high doses of leflunomide as well as teriflunomide, can inhibit other 
targets including protein tyrosine kinases, cyclooxygenase-2, PDK1, NFκB, integrins etc (Yara 
and Bidin 2015). The average steady-state maximum plasma concentrations (Cmax) of 
teriflunomide achieved with doses used in clinical trials are 72 µM (7 mg) and 168 µM (14 mg) 
(Oh and O’Connor 2013).  
Based on the current study, it can be expected that teriflunomide and its prodrug leflunomide 
should inhibit SOCE at clinically relevant dose. Such effect (SOCE inhibition at clinical dose) 
might contribute significantly to the observed biological effects and therapeutic benefits of 
these immunosuppressive drugs. Given the biological effect of teriflunomide and/or 
leflunomide, SOCE inhibition can be a potential target to down regulate the chemokines 
production, migration, and lymphocytes proliferation. Few recent studies have shown that 
SOCE inhibition can be an attractive strategy in treating such autoimmune diseases, this can 
be true as present study clearly demonstrated that these two drugs, which are being currently 
used as immunosuppressant, inhibit SOCE.  
Tolvaptan and conivaptan are orally and intravenously effective nonpeptide antagonists for the 
arginine vasopressin (AVP) receptor subtypes. These drugs promote water excretion without 
creating electrolytic imbalance, therefore these have been using for the treatment of 
hyponatremia (Aditya and Aditya 2012; Bhatt et al. 2014). 
 In this study tolvaptan ranked within the top 20 of the hits on the basis of ROCS and EON- 
based ranking. Conivaptan also ranked within top100 hits from Pyr6 and Synta66 based 
screening. Visually there were some similarities between the vaptans and the three individual 
baits (Fig. 3.1 and Fig. 3.2). Tolvaptan could inhibit SOCE significantly at 10µM dose whilst 
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conivaptan was active only at 100µM dose (Fig. 3.4). However, tolvaptan is unlikely to affect 
SOCE at therapeutic doses as the Cmax of this drug goes down at sub-micromolar level though 
a single 60 mg oral dose is subjected to human with normal kidney function (Shoaf et al. 2014).  
Omeprazole and lansoprazole are gastric proton pump inhibitors and as such are widely used 
in treating peptic ulcer as well as few other gastroesophageal diseases including Helicobacter 
pylori infection (Shin and Kim 2013). Both these drugs ranked within top 10 hits from AncoA4 
based screening (table 3.1), although omeprazole was within the top 50 hits on EON based 
ranking from screening with BTP2, Pyr6, and Synta66 (table 3.1). Apparently these two agents 
seemed to share some similarities with the baits (Fig. 3.1 and Fig. 3.2). Qualitatively, these 
two drugs seemed to share some similarities in surface electrostatics with the baits (Fig. 3.2). 
Although omeprazole looked better in computational analysis (table 3.1), but, lansoprazole 
was more potent in inhibiting SOCE (Fig. 3.4). However, the Cmax of lansoprazole and 
omeprazole at clinically relevant oral doses (15–30 mg) is likely to be ≤ 3.5µM (Shin and Kim 
2013), therefore very little effect of this drug on SOCE could be seen during clinical uses.  
Roflumilast is an orally administered drug, selective inhibitor of phosphodiesterase isoform 4 
(PDE4). This drug is known to treat inflammatory disease conditions in the lungs such as 
chronic obstructive pulmonary disease (COPD). Most of its pharmacological effects on PDE4 
inhibition (possibly up to 90%) can be attributed to its active metabolite roflumilast N-oxide 
(Rabe 2011). This drug was included in the tested drugs list due to its top rank in both BTP2 
and Pyr6 based screening using ROCS. At therapeutic doses (usually 500µg once a day), the 
Cmax of roflumilast N-oxide remains within low nanomolar range (Rabe 2011), and therefore 





























In chapter 1, out of 10 potential hits, 5 drugs, namely, leflunomide, teriflunomide, tolvaptan, 
lansoprazole and roflumilast, have found to supress SOCE significantly at £10µM dose. Apart 
from newly discovered SOCE inhibitory properties, these drugs have their own action 
mechanism which were already known.  
Leflunomide and its active metabolite teriflunomide are known to inhibit dihydroorotate 
dehydrogenase (DHODH) enzyme. The enzyme, DHODH is involved in the de novo 
pyrimidine nucleotides biosynthetic pathway through conversion of L-dihydroorotate (DHO) 
to orotate. This pathway is crucial for cell proliferation, therefore inhibition of the de novo 
nucleotide biosynthetic pathways offers therapeutic benefits for the treatment of autoimmune 
diseases, such as rheumatoid arthritis, multiple sclerosis and cancer (Vyas et al. 2014). In 
addition to leflunomide and its active metabolite teriflunomide, more DHODH inhibitors 
available in the market which are based on completely different chemo-types, while sharing 
the same clinical benefits. Brequinar, initially studied for anti-cancer properties (Joshi et al. 
1997) as well as vidofludimus and their analogues are few examples of well-known DHODH 
inhibitors (Leban et al. 2005).  
Not only drug or drug-like DHODH inhibitors were developed but also a handful number of 
non-drugs based DHODH inhibitors are now available. Efficient virtual screening strategy has 
facilitated identification of a wide range of chemo-diverse DHODH inhibitors. Some of these 
possessed novel scaffolds and showed distinct binding features with improved properties, such 
as better bioavailability, selectivity and potency. Thiazole, pyrazole, hydroxyazole and their 
analogues are some perfect examples of recently developed non-drug like DHODH 
inhibitors(Li et al. 2015).  
One of the best performing SOCE inhibitors in this study was Roflumilast, a selective inhibitor 
of phosphodiesterase isoform 4 (PDE4). PDE4 is one of the subclass of Phosphodiesterase 
(PDE) super family. PDE is a ubiquitous enzyme that enable to inactivate cyclic 3,5 adenosine 
monophosphate (cAMP) and 3,5 cyclic guanosine monophosphate (cGMP) through hydrolysis. 





PDE inhibitors have various pharmacological characteristics including anti-inflammatory, anti-
oxidant, vasodilator, cardiotonic and anti-cancer. Therefore these can be used as therapeutic 
agents for many diseases such as asthma, erectile dysfunction, depression, dementia, chronic 
obstructive pulmonary disease (Shafiee et al. 2017).  
Table 4.1 PDE families and their inhibitors (Victoria et al. 2006; Shafiee et al. 2017). 









Family Substrate Examples of inhibitors 
PDE1 cAMP/ cGMP nimodipine, vinpocetine, IC224, phenothiazines, and SCH51866 
PDE2 cAMP/ cGMP EHNA, BAY 60-7550, PDP, and IC933 
PDE3 cAMP/ cGMP Cilostamide, cilostazol, anagrelide, amrinone, milrinone, 
vesnarinone, motapizone, trequinsin 
PDE4 cAMP apremilast, crisaborole, ibudilast, luteolin, mesembrine, 
rolipram, piclamilast, roflumilast, tetomilast 
PDE5 cGMP Sildenafil, vardenafil, avanafil, mirodenafil, icariin, dasantafil, 
tadalafil  
PDE6 cGMP dipyridamole, vardenafil, tadalafil, zaprinast 
PDE7 cAMP ASB16165, IR- 202, US8637528, IR-284, BRL-50481 
PDE8 cAMP PF-04957325,  
PDE9 cGMP PF-04447943, BAY 73-6691 zaprinast  
PDE10 cAMP/ cGMP Papaverine, Azetidine  
PDE11 cAMP/ cGMP Dipyridamole, zaprinast, tadalafil   
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Lansoprazole was another SOCE inhibitors found in this study which belongs to proton pump 
inhibitors (PPIs) family. PPIs inhibits the gastric H+, K+-ATPase by covalent bonding at 
cysteines near the ion pathway. Their acid influx inhibition ability is due to the covalent bond, 
for this the inhibition lasts longer (Shin et al. 2006). 
PPIs have been used by care provider vastly as well as by modern gastroenterologist. For many 
people drug based PPIs represent the first choice for treatment of esophagitis, nonerosive reflux 
disease (NERD), peptic ulcer disease (PUD), prevention of nonsteroidal anti-inflammatory 
drugs (NSAID) associated ulcers, Zollinger-Ellison syndrome (ZES), and functional 
dyspepsia. Combined with antibiotics, PPIs act as an important part of eradication therapy for 
Helicobacter pylori (Strand et al. 2017). Since the discovery of first PPI, Omeprazole, till now 
more drugs include lansoprazole, pantoprazole, rabeprazole, esomeprazole and 
dexlansoprazole have been inaugurated. Recently, tenatoprazole, another novel PPI has 
undergone preliminary preclinical and clinical evaluation. Albeit these drugs have different 
substitution on their chemical ring which is different from each other, generally speaking they 
are almost similar in their pharmacological properties (Strand et al. 2017). 
Tolvaptan, a vaptan family drug, also found to be another potential SOCE inhibitor drug. The 
vaptans are non-peptide arginine-vasopressin-receptor (AVR) antagonists, that are orally and 
intravenously active. Arginine-vasopressin hormone is known to regulate osmolality by 
controlling urinary volume and composition (Bhatt et al. 2014). Peptide based AVR antagonists 
have been developed long ago. However, these antagonists have some crucial drawbacks when 
these apply to in vivo system. Peptide antagonists lost their antagonist effect, reversely showed 
an agonistic effect when taken chronically (Thibonnier et al. 2001). Non-peptide based AVR 
antagonists are being used for the treatment of euvolaemic or hypervolaemic hyponatraemia. 
These are also being taken for specific disorders such as cirrhosis and congestive heart failure 







Table 4.2 AVR families, mechanism, and inhibitors (Decaux et al. 2008). 
Table 4.2 summarizes different AVR families, their action mechanism and inhibitors. 
 
4.1.1 Aim of the project 
Using In silco based virtual screening followed by biological screening, five potential drugs 
were identified as SOCE inhibitors. Its mentioned earlier that these drugs are known to inhibit 
three distinct cellular paths; hence they were categorized as AVR antagonist, PPIs, and 
DHODH inhibitors class respectively. Although inhibitors from each class share the same 
clinical benefits but the potency, plasma concentration or selectivity varies due to their 
differences in structure and mode of action. Therefore, few more drugs, drug-like compounds 
and chemical scaffold from each class were further investigated aiming to get better SOCE 
inhibitor and also intriguing to know whether any SOCE inhibitory property, if there, is shared 
by all other members within the same class of inhibitors and also wanted to assess whether the 
observed SOCE-inhibitory property was due to the same pharmacophore used by these drugs 






Action mechanism Clinical development non-peptide 
antagonist 








V1b activates phosphatidylinositol 
and 1,2,-diacylglycerol 
signalling pathways 
Depressive disorders SSR-149415 
V2 activates the adenylyl cyclase 
signalling pathway through 












4.2.1 Selected arginine-vasopressin receptor (AVR) antagonists on SOCE 
To explore the effect of non-peptide AVR antagonists on SOCE, more 4 vaptans namely, 
mozavaptan, lixivaptan, OPC21268, SR49059 were purchased. SOCE inhibition was evaluated 
using fura-2/AM based Ca2+ imaging protocol described in chapter one. RBL-1 cells were 
loaded with 2µM fura-2/AM, stimulated by Tg to observe SOCE inhibition. Cells were pre-
incubated with each vaptan for ~15 min at 10µM dose. DMSO (0.01%) was pre-incubated in 
the cells as control group. When compared with control group, none of the vaptan caused any 
significant SOCE inhibition at 10µMdose (Fig 4.1), therefore, no further investigation was 



























































































Figure 4.1 Evaluation of AVR antagonists on the SOCE in RBl-1 cells.  
(a) Histograms showing the highest peak SOCE levels triggered by Tg in control cells and 
cells pre-treated with each VR antagonist at 10µM. (b) Sample traces representing Ca2+ 
triggered by adding Tg to cells with or without pre-treatment of the chosen drugs/compounds. 
Each value (mean ± SEM) was derived from 3-5 independent experiments done in different 















































































4.2.2 Evaluation of selected proton pump inhibitors (PPIs) on SOCE 
To get more PPI based SOCE inhibitors, additional 3 prazole and 2 non-prazole PPIs were 
further investigated. RBL-1 cells were incubated with each of the PPIs at 10µM dose for ~15 
min before doing single cell Ca2+ imaging. Data showing no PPI was capable to inhibit SOCE 




























Figure 4.2 Evaluation of PPI on the SOCE in RBl-1 cells.  
(a) Histograms showing the highest peak SOCE levels triggered by Tg in control cells and 
cells pre-treated with each PPI at 10µM. (b) Sample traces representing Ca2+ triggered by 
adding Tg to cells with or without pre-treatment of the chosen compounds. Each value (mean 
± SEM) was derived from 3-5 independent experiments done in different days with 50-60 
cells. One-way ANOVA followed by Dunnett’s test was used for statistical comparison. 
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4.2.3 Evaluation of some phosphodiesterase (PDE) inhibitor family on SOCE 
4.2.3.1 Selected phosphodiesterase type 4 (PDE4) inhibitor family on SOCE 
Additional 4 PDE4 inhibitors namely roflumilast N-oxide, apremilast, piclamilast, and 3,4-Bis 
roflumilast were evaluated with a view to finding whether any other member(s) within the 
PDE4 inhibitor class offer better potency towards SOCE inhibition. RBL-1 cells were pre-
incubated with each drug for ~15min before starting single Ca2+ imaging. DMSO (0.01%) and 
BTP2 (2µM) were included as negative and positive control respectively. Screening of the 
compounds was started with 10µM and at this dose only roflumilast N-oxide supressed SOCE. 
The very same molecule retained its SOCE inhibition ability at 3µM but failed to supress at 






































































































































































































































































Figure 4.3 Evaluation of the effects of PDE4 inhibitors on the SOCE in RBL-1. 
Histograms (left column) showing the highest peak SOCE levels triggered by Tg in 
control cells and cells pre-treated with each PDE4inhibitor at different doses (µM). 
Sample traces (right column) representing Ca2+ signals triggered by adding Tg to cells 
with or without pre-treatment of the chosen PDE4 inhibitors. Each value (mean ± SEM) 
was derived from 3-5 independent experiments done in different days with 40-90 cells. 
One-way ANOVA followed by Dunnett’s test was used for statistical comparison among 
groups and two-tailed unpaired t-test was used to compare data between groups. 
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4.2.3.2 More inhibitors from other PDE inhibitors family 
To find more potential SOCE inhibitors, selected inhibitors from different PDE inhibitor family 
were further investigated. For this, 7 drug-like compounds and small molecule, namely, 
trequinsin, Bay736691, BR1138, cilostamide, milirinone, rolipram, and BRL 50481 were 
purchased. Drugs treated for ~15 min in RBL-1 cells to start with single cell Ca2+ imaging. As 
mentioned earlier, fura-2/AM, a Ca2+ sensitive dye was loaded for ~40 min to prepare the cells 
to be imaged. DMSO and BTP2 were again included as negative and positive control 
respectively. At 10µM dose, of the seven agents only trequinsin and bay736691 have shown 
efficiency to inhibit SOCE. Trequinsin retained its ability to restrict SOCE entry at 3µM while 







































































































































































































































Figure 4.4 Evaluation of inhibitors from different PDE inhibitor family in RBL-1. 
Histograms (left column) showing the highest peak SOCE levels triggered by Tg in 
control cells and cells pre-treated with each PDE inhibitor at different doses (µM). 
Sample traces (right column) representing Ca2+ signals triggered by adding Tg to cells 
with or without pre-treatment of the chosen PDE inhibitors. Each value (mean ± SEM) 
was derived from 3-5 independent experiments done in different days with 40-80 cells. 
One-way ANOVA followed by Dunnett’s test was used for statistical comparison among 
groups and two-tailed unpaired t-test was used to compare data between groups. 
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4.2.3.3 Best performing PDE inhibitors in SHSY-5Y neuroblastoma cells 
Since trequinisn and roflumilast N-oxide were found to be the best performing PDE inhibitor 
to supress SOCE therefore these 2 compounds were taken into consideration to check whether 
the observed effect of these drugs on SOCE was cell-type specific or not. The drugs were tested 
against SHSY-5Y cells using the same protocol used for RBL-1 cells. Only trequinsin retained 



























































































Figure 4.5 Best performing PDE inhibitors on the SOCE in SHSY5Y cells.  
(a) Histograms showing the highest peak SOCE levels triggered by Tg in control cells and 
cells pre-treated with each PDE inhibitor at 10µM. (b) Sample traces representing Ca2+ 
triggered by adding Tg to cells with or without pre-treatment of the chosen PDE inhibitors. 
Each value (mean ± SEM) was derived from 3-5 independent experiments done in different 
days with 35-60 cells. One-way ANOVA followed by Dunnett’s test was used for statistical 
comparison. 
 73 
4.2.3.4 Best performing PDE inhibitors on TRPC-mediated Ca2+ entry 
Next experiment was executed to investigate to know whether these drugs could affect TRPC 
mediated Ca2+ entry which is triggered through addition of 1-oleoyl-2-acetyl-sn-glycerol 
(OAG). As can be seen in Fig. 4.6, none of the compounds at 10µM inhibited TRPC mediated 
Ca2+ entry triggered by 100µM OAG in RBL-1 cells. As excepted, known TRPC channel 



























































































Figure 4.6 PDE inhibitors on OAG-evoked Ca2+ entry in RBL-1 cells.  
(a) Histograms showing the peak OAG-activated Ca2+ entry in control cells and cells treated 
with 10µM of each PDE inhibitors. (b) Sample traces representing Ca2+ signals triggered by 
adding 100µM of OAG to RBL-1 cells with or without pre-treatment of the chosen PDE 
inhibitors. Each value (mean ± SEM) was derived from 3-5 independent experiments done 
in different days with of 30-70 cells. One-way ANOVA followed by Dunnett’s test was used 
for statistical comparison. 
 74 
4.2.3.5 Effects of selected PDE inhibitors on nuclear translocation of NFAT 
To see impact of the selected PDE inhibitors on SOCE-mediated Ca2+ dependent cellular 
signalling, further experimentation was executed. For this, effect of the agents on nuclear 
translocation of NFAT was tested in stably expressed NFAT1(1-460)-GFP HeLa cells. During 
experiment, cells were treated with the inhibitors and BTP2 for ~40 min followed by addition 
of Tg for 5 min. Qualitative and quantitative analysis of confocal images showing increased 
NFAT level in nuclear region for the control cells, but such augmentation was not observed for 

































































Figure 4.7 Selected PDE inhibitors on nuclear translocation of NFAT.  
(a) Representative confocal images of HeLa cells showing subcellular localisation of NFAT 
(1–460)-GFP following application of Tg (2µM for 40 min) preceded by pre-treatment with 
the chosen drugs (10µM) and BTP2 (2µM) for 30 min. (b) Bar graphs showing the nucleus to 
cytoplasm ratio (mean ± SEM, n= 3 independent days, 12-15 cells for each condition) for the 
NFAT (1-460)-GFP under various conditions. One-way ANOVA followed by Dunnett’s test 
was used for statistical comparison. 
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4.2.3.6 Selected PDE inhibitors on the oligomerisation of STIM1 and Orai1 
Having found some more drugs and drug-like molecules with SOCE inhibitory property, next 
the underlying mechanism for such action was investigated.  For this, a HEK293 cell line with 
an inducible mCherry-STIM1-T2A-Orai1-eGFP was used to evaluate effects of the agents on 
the clustering of STIM1 and also of Orai1. Before taking images using confocal microscopy, 
cells were treated with the inhibitors for an hour followed by addition of 2µM Tg. Qualitative 
and quantitively assessment showed there was no observed change in the punctate distribution 
of of mCherry-STIM1 or Orai1-eGFP in presence and absence of any of the PDE inhibitors 































































































































































































Figure 4.8 Selected PDE inhibitors on clustering of STIM-1 and Orai-1 protein.  
(a) Representative images of HEK293 cells co-expressing mCherry-STIM1 (red) and Orai1-
eGFP (green) showing translocation and colocalization of both proteins in characteristic 
puncta after treatment with Tg, no Tg and drugs. Quantification of mCherry-Stim1 (b) and 
GFP-Orai1 (c) puncta formation in response to Tg treatment and the effect of pre-treatment 
with drugs. The number of puncta formed in cells belonging to the control (no Tg) and the 
Tg-treated groups were expressed as mean/µm2 of area ± SEM. Each bar represents data from 
15-20 cells from 3 different experiments. One-way ANOVA followed by Dunnett’s test was 














































































































































































































4.2.4 Evaluation of some DHODH inhibitors on SOCE 
Two (2) defferent DHODH inhibitors were purchased to discover more potential SOCE 
inhibitors. Eight (8) drug-like and 3 chemical scaffolds of DHODH inhibitors namely, 
vidofludimus, brequinar sodium, atovaquone, ML390, 9090672,9099120 and STK485210 
were tested against SOCE channel in RBL-1 cells. Protocol already described before, briefly, 
cells were loaded with fura-2/AM dye for ~40 min and then washed with HBSS for twice 
followed by treatment of each compound for 15 min. DMSO and BTP2 were included as 


















































Data generated from single cell Ca2+ imaging showing, at 10µM dose, among all, vidofludimus 
and brequinar appeared to manifest the maximum suppression of the Ca2+ entry in RBL-1 cells. 
At 3µM, vidofludiumus retained its ability to restrict SOCE by ~80% whereas brequinar lost 
SOCE inhibitory efficiency at same dose. Vidofludimus kept continue its SOCE inhibitory 
































































































Figure 4.9 Effects of chosen drugs on the SOCE in RBL-1. 
Histograms (left column) showing the highest peak SOCE levels triggered by Tg (2µM) in 
control cells and cells pre-treated with each compound at different doses. Sample traces 
(right column) representing Ca2+ signals (indicated by fura-2/AM fluorescence ratio) 
triggered by adding Tg to cells with or without pre-treatment of the chosen compounds. 
Each value (mean ± SEM) was derived from 3-5 independent experiments done in different 
days with 35-70 cells. One-way ANOVA followed by Dunnett’s test was used for statistical 
comparison among groups and two-tailed unpaired t-test was used to compare data between 
groups. 
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4.2.4.1 Determination of IC50 for vidofludimus 
As vidofludimus significantly suppressed SOCE at 300nM (Fig. 4.9), therefore, complete 
concentration-response studies were carried out to determine the half-maximal inhibitory 
concentration (IC50) for this compound.  
As can be seen in Fig. 4.10, the compound showed dose-dependent suppression of SOCE over 
the concentration range of 30µM to 100nM. It would require ~1.4µM vidofludimus to curb 
















































Figure 4.10 Dose response curves (DRCs) for vidofludimus. 
Concentration-response curves demonstrating the dose-dependence of inhibitory effect of 
vidofludimus at µM dose on the SOCE in RBL-1 cells triggered by Tg. Each value (mean ± 
SEM) was derived from 3-5 independent experiments done in different days with 60-80 cells. 
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4.2.4.2 Vidofludimus on SOCE in SHSY-5Y neuroblastoma cells 
Since vidofludimus was found to be the best performing DHODH inhibitor to suppress SOCE 
therefore this compound was taken into consideration to check whether the observed effect of 
these drugs on SOCE was cell-type specific or not. The small molecule was tested against 
SHSY-5Y cells using the same protocol used for previous SHSY-5Y related experiment. 





































































Figure 4.11 Vidofludimus on the SOCE in SHSY5Y cells.  
(a) Histograms showing the highest peak SOCE levels triggered by Tg in control cells and 
cells pre-treated with each compound at 10µM. (b) Sample traces representing Ca2+ triggered 
by adding Tg to cells with or without pre-treatment of the chosen compound. Each value 
(mean ± SEM) was derived from 3-5 independent experiments done in different days with 
30-65 cells. Two-tailed unpaired t-test was used to compare data between groups. 
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4.2.4.3 SOCE inhibition in RBL-1 cells after prolonged incubation 
To evaluate whether longer incubation of vidofludimus could improve its potency for SOCE 
suppression, RBL-1 cells were pre-treated with the compound at 100nM for 48 hours. 









































































Figure 4.12 Vidofludimus on SOCE of RBL-1 cells following prolonged pre-treatment.  
(a) Histograms showing the peak SOCE levels triggered by Tg in control cells and cells pre-
treated with vidofludimus at 100nM for 48 hrs. (b) Sample traces of changes in Ca2+ signals 
following Tg (2µM) addition as well as Ca2+ add back under indicated conditions of pre-
treatment. Each value (mean ± SEM) was derived from 3-5 independent experiments done in 
different days with 70-80 cells. Two-tailed unpaired t-test was used to compare data between 
groups. 
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4.2.4.3 Vidofludimus on TRPC channel mediated Ca2+ entry 
Next experiment was executed to investigate whether vidofludimus could affect or not TRPC 
mediated Ca2+ entry, which is triggered through addition of OAG. Data showed, vidofludimus 
























Figure 4.13 Vidofludimus on OAG-evoked Ca2+ entry in RBL-1 cells.  
(a) Histograms showing the peak OAG-activated Ca2+ entry in control cells and cells treated 
with 10µM vidofludimus. (b) Sample traces representing Ca2+ signals triggered by adding 
100µM of OAG to RBL-1 cells with or without pre-treatment of the compound. Each value 
(mean ± SEM) was derived from 3-5 independent experiments done in different days with 



















































4.2.4.4 Testing vidofludimus on SOCE in Human Jurkat T cells 
Of the seven DHODH inhibitors, vidofludimus has shown highest potency on SOCE inhibition 
in various cell types therefore further testing this compound on human immune cell type was 
considered to check whether the observed effect was apposite to human physiology or not. To 
serve this aim, the compound was tested against human jurkat T-cells using the same protocol 
used for other Ca2+ imaging experiments. As can be seen in Fig 4.14, vidofludimus showed 
potency to supress SOCE in human jurkat T-cells not only at 10µM but also at 3µM dose. 




















Figure 4.14 Vidofludimus on the SOCE in human jurkat T cells.  
Histograms (left column) showing the highest peak SOCE levels triggered by 2µM Tg in 
control cells and cells pre-treated with vidofludimus at different doses. Sample traces (right 
column) representing Tg triggered-Ca2+ signals to cells with or without pre-treatment of the 
drug. Each value (mean ± SEM) was derived from 3-5 independent experiments done in 
different days with 35-50 cells. Two-tailed unpaired t-test was used to compare data between 
groups. 































































































































































































4.2.4.5 Effects of vidofludimus on nuclear translocation of NFAT 
To observe the impact of vidofludimus on SOCE-mediated Ca2+ dependent cellular signalling, 
further investigation was performed. For this, effect of the compound on nuclear translocation 
of NFAT was tested in stably expressed NFAT1(1-460)-GFP HeLa cells. During experiment, 
cells were treated with the drug and known SOCE blocker, BTP2 for ~40 min followed by 
addition of Tg for 5 min. Qualitative and quantitative analysis of confocal images showing 
increased NFAT level in nuclear region for the control cells, but such augmentation was not 
























Figure 4.15 Vidofludimus on nuclear transolcation of NFAT.  
(a) Representative confocal images of HeLa cells showing subcellular localisation of NFAT 
(1-460)-GFP following application of Tg (2µM for 40 min) preceded by pre-treatment with 
the drug (10µM) and BTP2 (2µM) for 30 min. (b) Bar graphs showing the nucleus to 
cytoplasm ratio (mean ± SEM, n= 3 independent days, 12-15 cells for each condition) for the 
NFAT (1-460)-GFP under various conditions. 
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4.2.4.5 Effects of vidofludimus on the oligomerisation of STIM1 and Orai1 
With a view to inquire possible mechanism underlying SOCE inhibitory properties of the drug 
further investigation was carried out. HEK293 cell line with an inducible mCherry-STIM1-
T2A-Orai1-eGFP was used to evaluate effect of the compound on the clustering of STIM1 and 
also of Orai1. Cells were treated with vidofludimus and known SOCE inhibitor, BTP2 for an 
hour followed by addition of 2µM Tg for 5 min. After that cells were imaged using confocal 
microscope. Qualitative and quantitative assessment showed, no change was observed in the 
punctate distribution of mCherry-STIM1 or Orai1-eGFP in presence and absence of the 








































































































































































Figure 4.16 Vidofludimus on clustering of STIM-1 and Orai-1 protein.  
(a) Representative images of HEK293 cells co-expressing mCherry-STIM1 (red) and 
Orai1-eGFP (green) showing translocation and colocalization of both proteins in 
characteristic puncta after treatment with Tg, no Tg and compounds. Quantification of 
mCherry-Stim1 (b) and GFP-Orai1 (c) puncta formation in response to Tg treatment and 
pre-treatment with compounds. Each bar represents data from 10-15 cells from 3 different 





In chapter 3, it was demonstrated that using virtual screening methodology followed by 
biological experimental procedure out of 10 chosen drugs, 5 drugs, namely, leflunomide, 
teriflunomide, tolvaptan, lansoprazole and roflumilast, have been found to supress SOCE 
significantly at £10 µM dose (Fig. 3.4). Besides SOCE inhibitory properties, these 5 SOCE 
inhibitory drugs have their own distinct known action mechanism. Currently, more analogues, 
drugs or drug-like compounds are available for each of the SOCE inhibitor class, therefore 
extended investigation was executed aiming to get more potent SOCE inhibitors from 
respective inhibitory class. 
To hunt more SOCE inhibitor with better potency, 4 non-peptides arginine-vasopressin 
receptor (AVR) antagonists, 5 proton pump inhibitors (PPIs); of them 3 prazole and 2 non-
prazole PPI inhibitors; 4 phosphodiesterase4 (PDE4) inhibitors, 7 other PDE family inhibitors 
and 7 dihydroorotate dehydrogenase (DHODH) inhibitors were purchased.  
Since the best performing drugs inhibited SOCE at ~10µM dose in chapter 3, therefore, goal 
of the present study was to find out any drug or compound that potentially would inhibit SOCE 
at lower than this concentration. For this reason, 10µM was the maximal dose used for any 
single cell Ca2+ imaging experiment in this study.  
AVR antagonists and PPIs were preincubated for ~15 min at 10µM dose, none of them showed 
any SOCE suppression (Fig. 4.1 and Fig 4.2) in single cell Ca2+ imaging experiment, therefore, 
no further studies were performed with these two classes inhibitors.  
From the PDE4 inhibitors, only roflumilast n oxide showed SOCE inhibition potency below 
10µM, eventually reached at 3µM (Fig. 4.3), the latter dose was lower than the minimal SOCE 
inhibitory dose of its pro-drug, roflumilast (Fig. 3.4). This means roflumilast N-oxide was 
better potent than its prodrug. After getting a better SOCE inhibitory compound from PDE4 
inhibitor family, other PDE inhibitor classes were included and tested them against SOCE in 
RBL-1 cells. Out of seven different PDE inhibitors, two of them, namely trequinsin, and 
Bay73966 inhibited SOCE at 10µM. Trequinsin retained its ability to supress SOCE at 3µM 
(Fig 4.4) which was egalitarian to PDE4 inhibitor, roflumilast n oxide. Due to vast number of 




At this point, trequinsin and roflumilast N-oxide, out of the eleven different PDE inhibitors, 
were found to be the best potent compounds against SOCE. It was worth to mention that both 
of these compounds have shown better efficiency than their homologous drug, roflumilast (Fig 
3.4) and their efficiency remain unchanged when tested in a different cell line such as SHSY5Y 
cells (Fig. 4.5).  
SOCE inhibition mediated by best performing PDE inhibitors was observed upon acute 
incubation of the compounds however, any potential effect of chronic incubation (~24hrs) of 
these compounds on SOCE was not investigated due the fact that their homologous drug, 
roflumilast previously failed to inhibit SOCE inhibition after longer treatment at lesser dose 
(1µM) (Fig. 3.7). 
In many cells including neurons, it has been found that store-depletion allows STIM proteins 
to activate some TRPC channels as well and Ca2+ via these channels then contribute to the 
SOCE observed (Liao et al. 2008). Best performing PDE inhibitors were tested against TRPC 
channel, however, no effect on TRPC was noticed (Fig. 4.6). This indicated their SOCE 
inhibition might be specific to Orai- mediated Ca2+ entry. Such proposition was set due to the 
fact hitherto molecular make-up of SOCE channel is largely unknown. One hypothesis 
proposed SOCE channels to be formed solely by Orai proteins whereas other one proposed, 
SOCE channels to be composed of both Orai and TRPC proteins(Zagranichnaya, Wu, and 
Villereal 2005; Hogan and Rao 2007; Liao et al. 2008). 
The next step was to see whether these two PDE inhibitors could affect nuclear translocation 
of NFAT or not. The later, already described, is widely known to be activated via SOCE 
mediated Ca2+ signals therefore NFAT translocation into nucleus can be disrupted by inhibition 
of SOCE, for instances in presence of SOCE blockers (Ishikawa et al. 2003). The effect of 
SOCE interruption on NFAT translocation can be studied using fluorescence-tagged NFAT 
(Prakriya and Lewis 2015). Given the observed SOCE-inhibitory property of the compounds, 
it was satisfying to see their complementary ability to retard nuclear translocation of 
NFAT1(1–460)-GFP in HeLa cells (Fig. 4.7).  
The possible mechanism action of SOCE inhibition by these compounds was something 
important to unravel. They might act intracellularly or could affect the clustering of STIM1 
and Orai1 when supressed Ca2+ entry. The former might not be the case because molecules 
were exposed for short period of time (~15min) which was possibly not enough to modify any 
intracellular mechanism.  
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Therefore, experiments were performed to chase the queries, in case if the agents could act 
either on Orai1 channels that are already activated due to Tg triggered ER store depletion via 
interaction with aggregated STIM1 proteins or these drugs may block SOCE extracellularly. 
Using confocal microscopy with a HEK293 cell line with an inducible mCherry-STIM1-T2A-
Orai1-eGFP, none of the drugs along with BTP2 showed any efficiency on either STIM1 
puncta formation or Orai1 puncta formation (Fig. 4.8). Hence SOCE inhibitory properties of 
these drugs could be attributed to their possible extracellular action, like acting as pore blocker. 
This presumption might be true and supported by previous study where researchers have shown 
that higher external Ca2+ concentrations are correlated with reduced BTP2 mediated SOCE 
inhibition (Zitt et al. 2004). Additionally. it can be proposed that these drugs might have 
unknown extracellular binding sites, however, this definitely requires direct experimental 
validation. This could be done by blocking the series of plasma membrane receptors through 
either pharmacological inhibitors or knocking down specific gene for the respective receptor. 
Since teriflunomide, a DHODH inhibitor exhibited better potency than other candidates in the 
earlier studies (Fig. 3.1) therefore a handful number of additional DHODH inhibitors were 
chased against SOCE in RBL-1 cells. Data from single cell Ca2+ imaging showing upon acute 
incubation, of the seven DHODH inhibitors, vidofludimus and brequinar sodium supressed 
SOCE at 10µM although latter compound did not show any inhibition at 3µM while the former 
appeared to inhibit SOCE at progressively lower doses unit it reached at 100nM (Fig. 4.9).  
Vidofludimus was the only candidate from 40 different drugs and compounds showed SOCE 
inhibition at nanomolar concertation in RBL-1 cells. Complete concentration-response study 
was carried out in RBl-1 cells to determine the IC50 for this drug and it appeared to display IC50 
of 1.4µM (Fig. 4.10) which was eventually the lowest IC50 dose in comparison to other potent 
SOCE inhibitors found in this study. Even this compound has shown more potency than known 
SOCE inhibitor, BTP2 that blocked SOCE in RBL-1 cell with IC50 of ~4.4µM (Fig. 3.5). 
It was interesting to see vidofludimus showed better potency to inhibit SOCE in comparison to 
similar class inhibitor, brequinar sodium. The latter case was discovered to be one of the 
strongest known inhibitor of human DHODH, with an IC50 of 1.8nM (Sainas et al. 2017) 
whereas vidofludimus was found to inhibit DHODH, with an IC50 of 134nM (Kulkarni et al. 
2010). This indicated SOCE inhibitory properties of these compounds as well as other DHODH 
inhibitors, were independent of their ability to inhibit DHODH. Hence it can be said that these 
compounds ensue a different way to supress SOCE other than their known action mechanism. 
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Like other SOCE inhibitors, vidofludimus also was not cell type specific to inhibit SOCE (Fig. 
4.10).  Although this molecule inhibited least significant SOCE at 300nM upon acute 
incubation but failed to retain this property during chronic treatment (~24hrs) of 100nM dose 
(Fig. 4.12). This was surprising as leflunomide and its metabolite teriflunomide though showed 
least significant SOCE inhibition at 10µM but effectual to supress SOCE at very lesser dose 
(01µM) upon chronic treatment (Fig. 3.7). This again pointed out that SOCE inhibitory 
property is possibly associated with incubation time and structural distinction of the 
compounds. Since TRPC proteins are conceivably part SOCE (Liao et al. 2008) therefore 
vidofludimus was examined against TRPC channel and this channel was found to be non-
affected by the compound (Fig 4.13). Hence presumably like other molecules, vidofludimus 
also may be specific to Orai-mediated SOCE inhibition. 
Vidofludimus, the most potent SOCE inhibitor found in this study, is known to inhibit 
interleukin 17 (IL-17) production in activated lymphocytes (Fitzpatrick et al. 2010), therefore 
any effect of this agent on SOCE in human immune cell type was an interesting observant. 
Human jurkat T cells was considered to serve this purpose. As expected this compound showed 
its potency to supress SOCE in jurkat T cells at relatively lower dose (3µM) (Fig. 4.14).  
The suggested mechanism of IL-17 inhibition by the compound was independent of DHODH 
inhibition (Fitzpatrick et al. 2010) rather due to hitherto known mechanism; attenuation of 
STAT3 and NF-κB-signalling pathways (Fitzpatrick et al. 2011), hence, SOCE inhibition in 
jurkat T cells indicated this compound might have a significant role in IL-17 production as well 
as other interleukins secretion. However, this definitely requires further experimental 
validation.  
Vidofludimus significantly restricted NFAT translocation in nucleus (Fig. 4.15) as well as 
didn’t affect either STIM1 puncta formation or Orai1 puncta formation (Fig. 4.16). Probably 
this molecule also shared the similar mechanism of action on NFAT translocation and STIM1-
Orai1 puncta formation demonstrated by other inhibitors, therefore any attributes and 































In calcium signalling cells secure the 'extra' Ca2+ as release from the internal stores, e.g., 
endoplasmic reticulum (ER) as well as entry from the extracellular space. The foremost Ca2+ 
entry mechanism in excitable cells occurs through voltage gated Ca2+ channels (VGCC) and 
through a distinct Ca2+ influx mechanism widely known as the store operated Ca2+ entry 
(SOCE) pathway in non-excitable cells (Berridge 1995; Berridge et al., 2000).  
Ca2+release via inositol 1,4,5-trisphosphate (IP3) signalling pathway 
In response to many stimuli (such as neurotransmitters, hormones and growth factors) G-
protein-coupled receptors located at the plasma membrane (PM) facilitate activation of 
phospholipase C (PLC). PLC catalyses the hydrolysis of phosphatidylinositol 4,5-bisphosphate 
(PIP2), a membrane bound phospholipid, to form both inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). DAG remains in the PM and activates protein kinase C (PKC). IP3 
diffuses through the cytosol and binds to and activates IP3 receptors located on the ER 
membrane. Opening of these channels allows Ca2+ to move down its concentration gradient 
from the ER (~500µM) into the cytosol (~100nM) and deplete ER stores through IP3Rs 
(Berridge 1993; Bootman et al. 2001). This bifurcating messenger system (IP3 and DAG) 
operates throughout the life of a typical cell, beginning with gametogenesis, fertilization, cell 
proliferation and early development and continuing through differentiation to perform very 









Figure 5.1 IP3 pathway. Binding of agonist to the plasma membrane initiates the signaling 
cascade that activates PLCγ, which cleaves PIP2, producing IP3. IP3 subsequently binds to the 
Ca2+ channel IP3 receptor in the endoplasmic reticulum (ER) membrane, triggering a release 
of Ca2+ from the ER stores into the cytoplasm. 
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Ca2+entry via voltage gated calcium channel (VGCC) pathway 
Voltage gated Ca2+ channels in many different cell types activates on membrane depolarization 
and mediate Ca2+ influx in response to action potentials and sub-threshold depolarizing signals. 
There are 10 members of the voltage-gated Ca2+ channel family in mammals, and they serve 
distinct roles in cellular signal transduction. 
Ca2+ entering the cell through voltage-gated Ca2+ channels serves as the second messenger of 
electrical signalling, initiating many different cellular events including contraction, secretion, 
synaptic transmission, enzyme regulation, protein phosphorylation/dephosphorylation, and 






















Figure 5.2 Voltage gated calcium channel pathway. In response to depolarizing changes 
in membrane potential, voltage-gated calcium channels rapidly open (within 1ms), raising 




5.1.1 Aim of the project 
Since Ca2+ release from ER via IP3 and entry from extracellular environment via VGCC are 
foremost parts of Ca2+ signalling, therefore any possible effect of SOCE inhibitors found in 
this study on both release and entry pathway were an undeniable step to investigate.  
The specific aims of this project were 
(a) investigating role of the selected SOCE inhibitors on ER-Ca2+ release via IP3 



























5.2.1 Evaluation of selected SOCE inhibitors on Ca2+ release from ER  
Effect of selected SOCE inhibitors, vidofludimus, trequinsin and teriflunomide, on Ca2+ release 
from ER was observed in SH-SY5Y neuroblastoma cells. Cells were loaded with 2µM fura-
2/AM for ~40 min and prepared for single cell Ca2+ imaging. Ca2+ release from ER was 
triggered due to addition of 100µM carbamylcholine (CCh) the latter is a widely used agonist 
of muscarinic acetylcholine receptors (mAChRs). CCh led to the depletion of ER Ca2+ through 
IP3-induced Ca2+ release. 
As can be seen in Fig. 5.3, vidofludimus significantly reduced Ca2+ release from ER triggered 






















































































Figure 5.3 Selected SOCE inhibitors on Ca2+ release from ER in SHSY5Y cells.  
(a) Bar diagram shows fluorescence peak ratio of CCh-evoked-Ca2+ release signals in 
control cells and cells pre-treated with drugs at 10µM. (b) Sample traces representing Ca2+ 
release signal triggered by CCh to cells with or without pre-treatment of the chosen 
compounds at 10µM. Each value (mean ± SEM) was derived from 3-5 independent 
experiments done in different days with 60-70 cells. One-way ANOVA followed by 
Dunnett’s test was used for statistical comparison. 
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5.2.2 Selected SOCE inhibitors on voltage gated channel Ca2+ entry 
In order to test whether these compounds had any effect on Ca2+ entry via voltage gated channel 
Ca2+, potassium chloride (KCl) evoked depolarization experiment was carried out in SHSY-
5Y cells. High concentration of KCl solution (70mM) depolarized the cells which then 
triggered extra cellular calcium entry into the cells. Data extracted from single cell Ca2+ 
imaging showing none of the selected compounds had any effect on voltage gated channel 
mediated Ca2+ entry (Fig. 5.4). As expected known calcium channel blocker, nifedipine, 





























































































Figure 5.4 Selected SOCE inhibitors on voltage-gated Ca2+ entry in SHSY5Y cells.  
(a) Bar diagram shows fluorescence peak ratio of voltage-gated Ca2+ entry in control cells 
and cells pre-treated with drugs at 10µM. (b) Sample trace representing voltage-gated Ca2+ 
entry triggered via 70mM KCl to cells with or without pre-treatment of the chosen 
compounds at 10µM. Each value (mean ± SEM) was derived from 3-5 independent 
experiments done in different days with 450-70 cells. One-way ANOVA followed by 




SHSY-5Y cells were chosen to study the effect of these compounds on IP3 and VGCC mediated 
Ca2+ signaling. Previously neuroblastoma and/or neural crest cell lines were used to study both 
IP3 evoked ER-Ca2+ release (Vaughan et al. 1995) and voltage dependent Ca2+ entry (Di 
Virgilio et al. 1987).  
It was interesting to see upon acute incubation (~15min), vidofludimus affected ER-Ca2+ 
release in SHSY-5Y cells (Fig. 5.3). This effect could be due to either extracellular occupancy 
of this compound to the binding site of the receptor in plasma membrane or intracellular 
blockade of IP3Rs, either case, could reduce ER-Ca2+ release. However, other unknown action 
mechanism might exist behind this phenomenon though such claim requires experimental 
evidences to support.  None of the compounds found to inhibit VGCC mediated entry upon 
KCl evoked depolarization (Fig. 5.4).  
As previously these compounds were not known to have any effect on Ca2+ signalling therefore 
any impact of these agents on Ca2+ signalling modification was added-knowledge to the 










































SOCE pathway over the years has been implicated in several diseases including severe 
Combined immunodeficiency (SCID) disorders, inflammatory bowel disease, 
neurodegenerative diseases, cardiovascular disorders and to various forms of cancers (Parekh 
2010; Roberts-Thomson et al. 2010). Ca2+ signalling including SOCE plays essential roles in 
a wide variety of cellular processes, from gene transcription to cell proliferation and 






















6.1.1 Aim of the project 
Best preforming SOCE inhibitors found in this study were tested sought to find any impact on 
biological processes. The aims of this project were to study the impact of the compounds on 
(a) cancer cell proliferation and  
(b) neuroblastoma cells differentiation.  
Figure 6.1 Proposed roles of SOCE in cancer. In tumor cells, SOCE promotes cancer cell 
proliferation via the upregulation of Cdc25C and the downregulation of p21. It also promotes 
cancer cell metastasis via the modulation of calpain- and Pyk2-mediated focal adhesion 
turnover or through upregulating the expression of COX-2, PGE2 and autotoxin. SOCE also 
contributes to drug resistance through an enhancement of AKT activity. In cancer cells, SOCE 
boosts the secretion of VEGF, which facilitates endothelial cell proliferation, angiogenesis 
and tumor growth. SOCE-mediated chronic inflammation through activation of Th17 cells is 
speculated to promote tumor growth. However, in NK, CD81 T and Th1 cells, SOCE is 




6.2.1 Evaluation of selected inhibitors on lung cancer cell proliferation 
To explore any effect of these compounds on cancer cell proliferation, three different lungs 
cancer cell line, named, H520, H1792, and LK2 were treated with the compounds for 72 hrs. 
Then adding cell counting kit for few hours followed by absorbance measurement using 
microplate reader, number of viable cells were detected from counting formazan formation. 
Fig. 6.2 showed dose dependence inhibitory effect of the compounds on cell proliferation 
different lung cancer cell line. pIC50 dose for each compound on different lung cancer cell lines 










































































a. H520 cells b. H1752 cells 
c. LK2 cells 
Figure 6.2 Does response curves (DRCs) for selected inhibitors. 
Concentration-response curves demonstrating the dose-dependence of inhibitory effect of 
indicated compounds on cell proliferation in (a) H520 cells (b) H1752 cells and (c) LK2 
cells. Each value (mean ± SEM) was derived from 3 individual experiments.  
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Table 6.1 shows half maximal inhibitory concentration (pIC50) of the compounds tested against 
different lung cells. pIC50 of these compounds vary depending on the cell types. 
 
6.2.1.2 SOCE inhibition in lung cancer cell at pIC50 dose 
To know whether cancer cell proliferation was due to SOCE inhibitory properties of these 
compounds or not, single cell Ca2+ imaging experiments were taken into consideration. Lung 
cancer cell lines were pre-incubated with the compounds at their respective pIC50 dose (table 
6.1) for ~15 min. Protocol already used in this study was followed for single cell Ca2+ imaging 
experiment. As can be seen in Fig. 6.3, each of the compounds supressed SOCE in different 
cell at their respective dose except compound, trequinsin, didn’t show such inhibition in H520 

















Cisplatin  ~3.79  ~2.562  ~7.62 
Teriflunomide  ~9.470  ~1.475  ~8.42 
Vidofludimus  ~8.096  ~3.188  ~9.36 
Brequinar sodium  ~2.018  ~4.098  ~1.86 
Trequinsin  ~1.49  ~3.51  ~4.04 


































































































































































































































































LK2 cells LK2 cells
Figure 6.3 Compounds on the SOCE in different lung cancer cells.  
Histograms (left column) showing the highest peak SOCE levels triggered by Tg in control 
cells and cells pre-treated with each compound at cell proliferation inhibiting dose. Sample 
traces (right column) representing Ca2+ triggered by adding Tg to cells with or without pre-
treatment of the chosen compounds. Each value (mean ± SEM) was derived from 3-5 
independent experiments done in different days with 40-60 cells. One-way ANOVA 
followed by Dunnett’s test was used for statistical comparison. 
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6.2.2 Selected SOCE inhibitors on SHSY5Y neuroblastoma cell differentiation 
If there any role on differentiation, compounds were tested against SHSY-5Y neuroblastoma 
cell. Each of compounds and retinoic acid (RA) were treated at 10µM for 10 consecutive days 
followed by bright filed images captured. Cells with neurite length and cell body ratio of ≥2 
were classed as differentiated. Qualitative and quantitative analysis showed none of the 
compounds including known SOCE inhibitor, BTP2, had any effect on SHSY-5Y cells 




























































































Figure 6.4 SOCE inhibitors on SHSY5Y neuroblastoma cell differentiation.  
(a) Images shown after treating cells with vehicle (EtOH), 10µM retinoic acid (RA) and 10µM 
each of the compound. Short branches (white arrow) and extended neurites (black arrow) 
represent non-differentiated and differentiated cells respectively. (b) Histograms showing the 
neurite length and cell body ratio after treating the cells with each compound. Each value 
(mean ± SEM) was derived from 3-5 independent experiments done in different days with 




Since SOCE is involved in many biological processes therefore chasing few of these processes 
aiming to observe any impact of selected SOCE inhibitors on them was an interesting part of 
this study.  
SOCE inhibitors on lung cancer cell proliferation 
SOCE has been recently implicated in various form of oncogenic transformation including 
malignant transformation, apoptosis, proliferation, angiogenesis, metastasis and antitumor 
immunity. It has regulatory effect on apoptic cell death, proliferation and metastasis of cancer 
cells (Xie et al. 2016). Targeting SOCE using pharmacological modulator to control cancer has 
recently got attention in the cancer research field. Hence the most potent SOCE inhibitors found 
in this study were tested against different lung cancer cells. Data from cell proliferation assay 
showed tested compounds had diverse effect on proliferation and such effects were cell type 
specific (table 6.1). Cisplatin, an important chemotherapeutic drug, used in the treatment of 
advanced cancer, also have shown anti-proliferative effect tested in lung cancer cell (Li et al. 
2013). Of the tested compounds, overall brequinar sodium have shown realtibely better anti-
proliferative action in every cell line. Trequinsin showed almost similar fashion of inhibition 
as brequinar did. On the other hand, overall, teriflunomide and vidoflunomide were relatively 
less potent against proliferation LK2 and H520 cells although both of the compounds were 
very effective on anti-proliferation when tested against H1752 cell (table 6.1).  
It was not surprising to observe anti-proliferative properties of these compound in lung cancer 
cell line. Recently it has been reported that both brequinar and teriflunomide (A771726) 
inhibited proliferation of various cancer cell lines including human melanoma (A375), human 
myeloma (H929), and human Burkitt’s lymphoma (Ramos) cell lines (Dorasamy et al. 2017). 
Though not trequinisn but other PDE3 family compounds have been reported previously to 







To find any relevance between anti-proliferative properties and SOCE, all the compounds were 
then tested against SOCE at pIC50 dose in the very same lung cancer cell lines. Except 
trequinsin, which didn’t inhibit SOCE in two of the cell lines at pIC50 dose, all other 
compounds supressed SOCE at such concentration (Fig. 6.3). Collectively, it can be said that 
SOCE inhibition and anti-proliferative activity of these compounds may be mutually inclusive 
and SOCE inhibitory properties of these compounds might have contribution on inhibition of 
proliferation. However, they could act through a different path other than SOCE to show anti-
proliferative activity which again required experimental validation. 
SOCE inhibitors on SHSY-5Y neuroblastoma cell differentiation 
SOCE have been recently explored in neurogenesis, neural development, proliferation and 
differentiation (Hao et al. 2014; Somasundaram et al. 2014; Gopurappilly et al. 2018). SOCE 
also been reported to have role on differentiation in non-neuronal cells (Darbellay et al. 2009). 
Therefore, selected SOCE inhibitors were tested sought to find if there is any effect on 
differentiation of SHSY-5Y neuroblastoma cells.  
Compounds, as well as retinoic acid (RA) were treated at 10µM for 10 consecutive days in the 
experimental procedure. RA is known to induce growth seize and differentiation in human 
neuroblastoma cells (Sidell N 1982). Therefore, RA as expected, induced differentiation in 
SHSY-5Y cells while none of the drugs exhibited any differentiation effect on this cell type 
(Fig. 6.4). Although statistically insignificant, visual observation indicated trequinsin was 
better than other compounds in terms of number of differentiated cells formed (Fig. 6.4). 































Myelin sheaths consist of highly organized lipid-rich membrane stacks surrounding axons, the 
conductive processes of neurons. The presence of myelin sheaths results in axons with high 
resistance and low capacitance. This enables efficient and rapid saltatory propagation of nerve 
impulses (Squire et al. 2003) as well as play an important role in maintaining and protecting 
axons (Irvine and Blakemore 2008). As myelin sheaths seem to provide trophic support to 
myelinated axons, therefore one of ways to protect axons in the context of disease therefore is 
to ensure that myelin sheaths are maintained, or if lost that they are rapidly regenerated. 
In central nervous system (CNS), there is a process called remyelination, by which the entire 
myelin sheath is restored as well as the saltatory conduction and the functional deficits 
(Franklin and ffrench-Constant 2008). Remyelination or myelin regeneration in the adult CNS 
is mainly mediated by a multipotent parenchymal CNS stem/progenitor cell population 
traditionally referred to as oligodendrocyte progenitor cells (OPCs). Following a demyelinating 
incident, OPCs are rapidly amplified in areas of demyelination where they subsequently give 
rise to myelinating oligodendrocytes (Franklin 2002; Franklin and ffrench-Constant 2008). 
Successful remyelination depends mostly on the OPCs recruitment into the demyelinated area 
and their subsequent engagement of denuded axons and finally their differentiation into mature 












Figure 7.1 OPCs differentiation process.  
Differentiation steps of OPCs forming an immature precursor to the mature oligodendrocyte. 
Figure is taken from Angela et al. 2020. 
 
 
Bipolar OPCs  
 





During normal development, the maturation of the oligodendrocyte lineage cells destined to 
trigger myelinogenesis takes place according to sequential stages represented by temporal 
expression of some cell surface markers and morphology. The stages are oligodendrocyte 
progenitors and precursors, pre-oligodendrocytes, and non-myelinating/immature and 
myelinating mature oligodendrocytes (Liu et al. 2002). 
Proliferation of OPCs 
During the early embryonic life, OPCs originate from the neuroepithelium of the ventricular 
region. OPCs are highly proliferative and motile bipolar cells. Several mechanisms have been 
suggested to control OPC proliferation. One of the mechanisms was reported to be limited by 
intrinsic clock through which OPCs passthrough confine number of divisions before 
differentiated to myelin forming oligodendrocytes (Temple and Raff 1986). However, this 
mechanism was found to be completely dependent on external environmental factors (Calver 
et al. 1998).  
Neuron-derived growth factors act as effective mitogens for OPCs. Platelet-derived growth 
factor (PDGF-AA) is thought to be the most potent OPC mitogen which is found to be 
abundantly expressed in OPCs as well as happen to be down-regulated when the OPCs 
differentiate into mature oligodendrocyte (Calver et al., 1998). Proteoglycan NG2 (neuron-glia 
antigen 2) also has influence on OPCs proliferation via acting as co-receptor for PDGFRα 
(Goretzki et al. 1999). Deletion of NG2 in mice reduced OPCs number which indicates NG2 
enhance OPCs proliferation (Kucharova and Stallcup 2010). Fibroblast growth factor (FGF) 
appeared to enhance OPCs proliferation by regulation of developmental changes of FGF 
receptor expression, with FGF-3 receptors being abundantly expressed by OPCs and 
downregulated as OPCs differentiate into myelinating oligodendrocytes (Bansal et al. 1996). 
Few other growth factors including brain derived neurotrophic factor (BDNF) (Van't Veer et 
al. 2009), neuregulin (Roy et al. 2007) and neurotrophin-3 (NT-3) (Barres et al. 1994b) also 
have shown mitogenic activity which enhance OPCs proliferation.  
In contrary to those that enhance OPCs proliferation, few messengers have been found to 
inhibit the process. Especially retinoic acid and thyroid hormone allow OPCs to exit cell cycle 
and start differentiation (Barres et al. 1994a). The mechanism by which these molecules stop 
cell cycle and induce differentiation of OPCs is yet to be known precisely.  
In addition to growth factors, neurotransmitters may be involved in regulation of OPCs 
proliferation. It is already well known that OPCs receive synaptic input mediated by 
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neurotransmitters like glutamate and GABA, which indicated these could also regulate 
developmental process of OPCs (Karadottir et al. 2008). 
Differentiation of OPCs 
During developmental processes a large number of proliferated OPCs differentiate into non-
myelinating or immature oligodendrocytes which then differentiate into myelin forming 
oligodendrocytes (Zhu et al. 2008; De Biase et al. 2010; Kukley et al. 2010). 
As OPCs differentiate into mature oligodendrocytes, expression of some specific proteins 
(molecular marker) as well as their morphology undergo significant changes. Although 
oligodendrocyte lineage expression marker SOX10 and Olig2 do not alter during the entire 
developmental process but as soon as OPCs start losing lose expression of precursor proteins 
including NG2 and PDGFRα, immature marker O4 expression begin followed by expression 
of mature markers including PLP, galactocerebroside and myelin basic protein (MBP) 
(Nishiyama et al. 2009). Although OPCs are distributed evenly throughout the brain from the 
birth, however, not all OPCs differentiate into myelinating oligodendrocytes; a significant 
portion remain non-differentiated oligodendrocytes (Dawson et al. 2003; Rivers et al. 2008; 
Psachoulia et al. 2009).  
Several molecular signalling molecules including growth factors, retinoic acid, glucocorticoid 
and thyroid hormone and neurotransmitters have been reported to cause OPCs cell cycle arrest 
and differentiate, however, mechanisms behind the post mitotic switching were largely 
unknown, although study showed differentiated OPCs express series of microRNAs which 
probably explain de novo level of gene expression (Bartel 2004). Withdrawal of some mitogens 
from OPCs culture found to induce expression of specific miRNAs (Zhao et al. 2010) and these 
miRNAs effectively downregulate the responsiveness of OPCs to the signal molecule which 
resultant a change in expression of some OPC-specific genes that eventually promote 
differentiation (Dugas et al. 2010; Zhao et al. 2010). This gives a clue to develop molecules 
that could regulate OPCs development and promote differentiation by changing gene 
expression. 
Not only intrinsic factors like RA and T3 hormone receptors, basic helix-loop-helix (bHLH), 
Sox-family, zinc finger transcription factors actively promote oligodendrocyte differentiation 
but other signalling pathways like cAMP-Erk1/2/p38Mapk-Creb1 signalling (Syed et al. 2013) 
are also important for OPC differentiation. Recent time, a few clinically relevant, FDA 
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approved compounds also found to OPCs differentiation (Deshmukh et al. 2013; Mei et al. 
2014; Najm et al. 2015; Franklin 2015; Neumann et al. 2019). 
Myelination 
Differentiated oligodendrocytes extent myelin sheaths which then can be wrapped around 
axonal tracts spirally. But there is no single proposition of wrapping mechanism rather several 
methods have been suggested till date.  Myelin membrane can be wrapped into several layers 
and wrapping could start from outer part of the myelin sheath, electron microscopy studies 
showed (Snaierdo et al. 2014). 
Not all the axons become myelinated, but only axons with thickness of a certain diameter while 
thinner axons remain non-myelinated. However, how oligodendrocyte processes recognize 
axons and vice versa as well as provide trophic support to neurons, are not fully understood yet 
(Fünfschilling et al. 2012; Simons and Lyons 2013).  
 
7.1.1 Role of SOCE in OPC biology 
Ca2+ as a ubiquitous and versatile second messenger, is well-known to regulates numerous 
developmental events in the brain, including neural induction, neurotransmitter specification, 
growth cone motility, differentiation, growth and proliferation, and neuronal maturation 
(Nakanishi and Okazawa 2006; Toth et al. 2016).   
Several studies have addressed the importance of Ca2+ signalling in OLGs differentiation and 
myelination as well as in process extension and OLGs migration and retraction of membrane 
sheets and cell death in mature mouse OLGs (reviewed by Walsh et al. 2010). 
SOCE and its underlying protein players (STIM, Orai isoforms) are traditionally believed to 
be important for regulating various aspects of the biology of the non-excitable cells mainly. 
However, this notion is changing, and evidence amass that SOCE is present and functional in 
many excitable cells including neurons. Studies implicate SOCE in modulating several 
neuronal functions, including neurotransmitter release, synaptic plasticity, Ca2+ oscillations, 
and firing of flight motor neurons in Drosophila (Venkiteswaran and Hasan 2009). Moreover, 
aberrant SOCE has been implicated in hypoxia-mediated neuronal death, epilepsy, and the 
response to axonal injury. SOCE represents an important mode of Ca2+ delivery for the non-
excitable cells of CNS. Recently it has been evident that SOCE channels regulate gene 
expression and proliferation in neural progenitor cells (Somasundaram et al. 2014).  
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A very few studies have been conducted so far to investigate SOCE in OPCs biology. In the 
recent past researchers have shown SOCE modulation enhanced OPCs proliferation by the golli 
products of the myelin basic protein gene in golli-overexpressing and golli-KO mice (Paez et 
al. 2009; Paez et al. 2011). Nevertheless, the molecular mechanisms of Ca2+ signalling tool 
kits, particularly the SOCE channel during the OPCs development and their physiological 
functions in proliferation, migration, differentiation and remyelination remain poorly 
characterized. 
7.1.2 Background of the project 
In multiple sclerosis (MS), a demyelinating disease, under several circumstances, axons 
become demyelinated. One of the major causes for primary demyelination in CNS is the 
inflammation (Franklin and ffrench-Constant 2008). Identification of small molecules, or a 
signalling pathway that selectively induce differentiation of OPCs at areas of demyelinated 
lesions and thereby improve remyelination would have a significant impact on the future 
treatments (MS).  
During the initial phase of my PhD work, Teriflunomide and its pro-drug, leflunomide were 
found to be able to suppress SOCE significantly at doses that are clinically-achievable (Fig. 
3.4). Teriflunomide has been approved as an oral disease-modifying therapy for treating 
relapsing or relapsing-remitting multiple sclerosis (RR-MS) (Confavreux et al. 2014). As 
teriflunomide, a drug for RR-MS, blocked SOCE at clinically-relevant concentration (~10µM) 
(Claussen and Korn 2012; Mehta et al. 2009), therefore it was hypothesized that SOCE-
modulatory properties of this drug may also contribute to the observed clinical benefits in MS. 
Therefore, I sought out to evaluate SOCE in the context of OPC biology and specifically 
pursued the following aims:  
(a) basic characterisation of SOCE in OPCs 





















































7.2.1 Isolation of OPCs 
Isolation OPCs was the starting point of this project and for this, two different methods were 
employed. Mixed glia culture (MGC) shaking method proposed by McCarthy and de Vellis, 
1980 (see methods section for details) was used to isolate OPCs from neonatal rat brain, aged 
between P0 to P2, whereas using magnetic activated cell sorting (MACS) method (see methods 
section for details) OPCs were collected from P5-P7 aged rat brain. Approximate yield of 0.5 
x 107 cells from each brain were obtained through both methods. After 24 hrs, cells were 
immunostained to see the OPCs enrichment, cell population obtained via MACS procedure 
were more enriched in OPCs than MGC shaking method. An estimation of 20-30 percent of 
microglial and astrocytic contamination were noticed in cell population (Fig.7.1). Cells isolated 
















Figure 7.1 Purity level of OPCs population.  
Representative images of OPCs isolated from neonatal rat brain using (a) MGC and (b) 
MACS procedure. OPCs, microglia and astrocytes were stained with antibodies olig2, 
CD11b and GFAP respectively. Histograms showing enrichment of OPCs (%) in total cell 
























a. OPCs in 2DIV b. OPCs in 4DIV c
7.2.2 Maintaining OPCs culture and generating mature oligodendrocytes (OLGs) 
Fostering OPCs culture and yielding OLGs were required incessantly for different 
experimental procedures throughout this project. Hence OPCs were maintained in proliferation 
medium supplemented with daily addition of 10ng/ml growth factors; PDGF-AA and basic 
bFGF while OLGs were produced by growing OPCs in differentiation medium supplemented 
with daily addition of 50ng/ml T3 (Triiodo-L-Thyronine) hormone. After respective treatment, 
significant increase of OPCs (Fig. 7.2) and OLGs (Fig. 7.3) were observed after 4 days in vitro 



















Figure 7.2 Maintaining OPCs in culture.  
Representative images showing OPCs after (a) 2DIV and (b) 4DIV. OPCs lineage and 
newly formed OPCs were immune stained with antibodies olig2, and Ki67 respectively. (c) 
Histogram showing increasing of OPCs number at different days. Each value (mean ± SEM) 
was derived from 3 individual experiments. Two-tailed unpaired t-test was used to compare 


















































Figure 7.3 Generation of oligodendrocytes (OLGs).  
Representative images showing OLGs after (a) 2DIV and (b) 4DIV. OPCs lineage and mature 
oligodendrocytes (OLGs) were immune stained with antibodies olig2, and MBP respectively. 
(c) Histogram showing increasing of OLGs number at different days. Each value (mean ± 
SEM) was derived from 3 individual experiments. Two-tailed unpaired t-test was used to 















































7.2.3 Characterization of SOCE in OPCs 
7.2.3.1 SOCE activation in OPCs via pharmacological mean 
To study SOCE, OPCs were obtained from 4DIV culture maintained in proliferation medium. 
Extracellular Ca2+ entry was observed in OPCs loaded with 4µM fura-2/AM, stimulated by 
2µM Tg (Fig. 7.3). Known SOCE inhibitors, BTP2 and AncoA4, were included as positive 
control group and each of the compounds was preincubated for ~15 min prior to executing 
single cell Ca2+ imaging experiment. As expected, known inhibitors supressed SOCE in OPCs 



















Figure 7.4 Pharmacological activation of SOCE in OPCs.  
(a) Histograms showing the highest peak SOCE levels triggered by Tg (2µM) in control cells 
and cells pre-treated with AncoA4:10µM, and BTP2:2µM. (b) Sample traces representing 
Ca2+ signals triggered by adding Tg to cells with or without pre-treatment of the chosen 
compound. Each value (mean ± SEM) was derived from 3-5 independent experiments done 


















































7.2.3.2 SOCE activation in OPCs via physiological mean 
To see whether physiological ligands could activate SOCE in OPCs obtained from 4DIV 
culture, similar protocol was used except Tg was replaced by PDGF-AA. As can be seen in 
Fig. 7.5, SOCE was activated in OPCs by addition of 40nl/ml PDGF-AA as well suppressed 





















Figure 7.5 SOCE triggered in OPCs via physiological mean.  
(a) Histograms showing the highest peak SOCE levels triggered by PDGF-AA at 40ng/ml in 
control cells and cells pre-treated with BTP2 at 2µM dose. (b) Sample traces representing 
Ca2+ signals triggered by adding PDGF-AA to cells with or without pre-treatment of BTP2. 
Each value (mean ± SEM) was derived from 3-5 independent experiments done in different 






















































7.2.3.3 Evaluation of teriflunomide on SOCE in OPCs  
As mentioned earlier, teriflunomide which is an approved drug for MS, was found to be 
inhibiting SOCE in immune (RBL-1H and human jurkat T cells) and human neuroblastoma 
cells (SHSY-5Y). After basic characterisation of SOCE in OPCs (see above), I was sought out 
to know, using standard experimental protocol, whether this drug could affect SOCE in OPCs 
as well. As can be seen in Fig.7.6, acute incubation (15min) of OPCs with 10µM teriflunomide 
























Figure 7.6 Teriflunomide on SOCE in OPCs.  
(a) Histograms showing the highest peak SOCE levels triggered by Tg:2µM in control cells 
and cells pre-treated with 10µM teriflunomide. (b) Sample traces representing Ca2+ signals 
triggered by adding Tg to cells with or without pre-treatment of teriflunomide. Each value 
(mean ± SEM) was derived from 3-5 independent experiments done in different days with 

















































7.2.3.4 TRPC channel mediated Ca2+ entry in OPCs 
There have been few reports about the existence of TRPC channels in OPCs (Paez et al. 2011). 
Therefore, next experiment was executed to investigate TRPC mediated Ca2+ entry in OPCs 
obtained from 4 DIV culture and for this, standard Ca2+-imaging protocol was used but Tg was 
replaced by OAG. As can be seen in Fig. 7.7, OPCs exhibited robust rise in cytoplasmic Ca2+ 
concentrations upon application of 150µM OAG in the bath solution. The signal represented 
Ca2+ entry since it was discernible only after adding Ca2+ to the bath solution. Since the known 
TRPC blocker, SKF96365 at 15µM almost abolished the Ca2+ signal, it indicated that the OAG-
evoked Ca2+ signal observed in OPCs was attributed to TRPC-mediated Ca2+ entry in these 























Figure 7.7 TRPC mediated Ca2+ entry in OPCs.  
(a) Histograms showing the peak OAG-activated Ca2+ entry in control cells and cells treated 
with 15µM SKF96365. (b) Sample traces representing Ca2+ signals triggered by adding 
150µM of OAG to OPCs with or without pre-treatment of SKF96365. Each value (mean ± 
SEM) was derived from 3-5 independent experiments done in different days with 40-45 
cells. Two-tailed unpaired t-test was used to compare data between groups. 
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7.2.3.5 SOCE differences between OPCs and OLGs  
 OPCs and OLGs were obtained from 4DIV culture maintained in presence and in absence of 
growth factors respectively to investigate difference of SOCE between OPCs and OLGs. SOCE 
was triggered in both cell types through pharmacological mean, Tg and data from single cell 
Ca2+ imaging experiment demonstrated no significant difference in the magnitude of SOCE 






















Figure 7.8 SOCE differences between OPCs and OLGs cells.  
(a) Histograms showing the highest peak SOCE levels triggered by Tg (2µM) in OPCs and 
OLGs cells (b) Sample traces representing Ca2+ signals triggered by adding Tg to both OPCs 
and OLGs cells. Each value (mean ± SEM) was derived from 3-5 independent experiments 



































































































7.2.4 Investigation of voltage-gated Ca2+ channel (VGCC) entry in OPCs 
 In order to test whether OPCs could also support Ca2+ entry via voltage-gated Ca2+ channel 
(VGCC), KCl-evoked depolarization experiment was carried out in OPCs generated from 
4DIV culture. Upon addition of high concentration of KCl (70mM) cells became depolarized 
which then triggered extra cellular calcium entry. Data extracted from single cell Ca2+ imaging 
showing OPCs allow voltage gated channel mediated Ca2+ entry since nifedipine - a known 























Figure 7.9 Voltage-gated Ca2+ entry in OPCs.  
(a) Bar diagram shows fluorescence peak ratio of voltage-gated Ca2+ entry triggered by  
70mM KCl in control cells and cells pre-treated with nifedipine at 3µM. (b) Sample trace 
representing voltage-gated Ca2+ entry signal in OPCs with or without pre-treatment of 
nifedipine. Each value (mean ± SEM) was derived from 3-5 independent experiments done 
in different days with 45-60 cells. Two-tailed unpaired t-test was used to compare data 
between groups. 
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7.2.5 SOCE in OPCs differentiation 
7.2.5.1 OPCs differentiation upon SOCE inhibition triggered by BTP2 
To investigate any possible role of SOCE on OPCs differentiation, one of the widely used 
known SOCE inhibitors, BTP2 (Ishikawa et al. 2003; Zitt et al. 2004; He et al. 2005) was used. 
OPCs maintained in differentiation medium without T3 hormone, were treated with vehicle or 
BTP2 for 2 days. BTP2 was used at concentration ranging from 1µM to 10nM. Afterwards, 
cells were immune stained against respective antibodies. Fig. 7.10 demonstrated a significant 
increase of myelin basic protein (MBP) positive cells only at 100nM of BTP2. MBP is 


















Figure 7.10 OPCs differentiation upon SOCE inhibition triggered by BTP2.  
(a) Representative images of MBP-positive OPCs treated with vehicle or BTP2 at 
concentrations ranging from 10nM to 1µM. Olig2 and MBP expression are the markers for 
OPCs lineage and differentiation respectively. (b) Bar graph evaluating OPCs differentiation-
promoting efficacy in the presence or absence of BTP2 at concentrations ranging from 10nM 
to 1µM after 2 days. Each value (mean ± SEM) was derived from 3 individual experiments. 
One-way ANOVA followed by Dunnett’s test was used for statistical comparison.  
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7.2.5.2 OPCs differentiation upon SOCE inhibition triggered by AnCoA4 
To see whether any SOCE channel protein had any involvement on OPCs differentiation, 
Orai1, (SOCE channel protein) inhibitor, AnCoA4 (Sadaghiani et al. 2014) was included to 
test this hypothesis. OPCs maintained in differentiation medium without T3 hormone were 
treated with vehicle and AncoA4 at concentrations used ranging from 50nM to 3µM for 48 hrs. 
At 300nM dose, AncoA4 showed most differentiation whereas it was lesser at 1µM, both cases 























Figure 7.11 OPCs differentiation upon SOCE inhibition triggered by AnCoA4.  
(a) Representative images of MBP-positive OPCs treated with vehicle or AnCoA4 at 
concentrations ranging from 50nM to 3µM. Olig2 and MBP expression are the markers for 
OPCs lineage and differentiation respectively. (b) Bar graph evaluating OPCs differentiation-
promoting efficacy in the presence or absence of AnCoA4 at concentrations ranging from 
50nM to 3µM after 2 days. Each value (mean ± SEM) was derived from 3 individual 




























7.2.5.2 Effect of TRPC channel inhibition on OPCs differentiation 
Next step was to test any effect of TRPC channel inhibition on OPCs differentiation, for this 
OPCs maintained in differentiation medium without T3 hormone were treated with vehicle 
control and different doses of TRPC channel inhibitor, SKF96365, ranging from 50nM to 3µM 
for 48 hrs. Immunostaining data revealed that TRPC channel blocker enhanced OPCs 























Figure 7.12 Effect of OPCs differentiation on TRPC channel inhibition.  
(a) Representative images of MBP-positive OPCs treated with vehicle or SKF96365 at 
concentrations ranging from 50nM to 3µM. Olig2 and MBP expression are the markers for 
OPCs lineage and differentiation respectively. (b) Bar graph evaluating OPCs differentiation-
promoting efficacy in the presence or absence of SKF96365 at concentrations ranging from 
50nM to 3µM after 2 days. Each value (mean ± SEM) was derived from 3 individual 



























7.2.5.3 Effect of teriflunomide on OPCs differentiation 
As mentioned earlier, teriflunomide, a drug for MS, was found to block SOCE, therefore effect 
of this drug on OPCs differentiation was further investigated. OPCs maintained in 
differentiation medium without T3 hormone were treated with vehicle or different doses of 
teriflunomide for 48 hrs to test this hypothesis. As can be seen in Fig. 7.13, teriflunomide 





















Figure 7.13 Effect of teriflunomide on OPCs differentiation.  
(a) Representative images of MBP-positive OPCs treated with vehicle or teriflunomide at 
concentrations ranging from 1µM to 10µM. Olig2 and MBP expression are the markers for 
OPCs lineage and differentiation respectively. (b) Bar graph evaluating OPCs differentiation-
promoting efficacy in the presence or absence of teriflunomide at concentrations ranging from 
1µM to 10µM after 2 days. Each value (mean ± SEM) was derived from 3 individual 




























7.2.6 Effect of the SOCE and TRPC channel inhibitors on OPCs proliferation 
Since SOCE and TRPC channel inhibitors have shown to enhance OPCs differentiation 
therefore any potential role of these compounds on OPCs proliferation at differentiation-
promoting dose was taken into consideration for further investigation. OPCs maintained in 
proliferation medium were treated with BTP2, AnoCA4 and SKF96365 for 48 hrs, no growth 
factor was added, whereas vehicle control was maintained for the same time period with daily 
addition of 10ng/ml growth factors; PDGF-AA and bFGF. Data extracted from immune stained 
images showing none of the compounds had any ability to increase proliferation at 
differentiation-promoting dose compare to growth factors treated group (Fig. 7.14). Compound 
treated group has got significantly a smaller number of Ki67 positive cells than control (Fig 

















Figure 7.14 SOCE and TRPC channel inhibitors on OPCs proliferation.  
(a) Representative images of Ki67-positive OPCs treated with vehicle or BTP2, AnCoA4 
and SKF96365 at differentiation promoting doses. Olig2 and Ki67 expression are the 
markers for OPCs lineage and newly formed OPCs respectively. Inset picture depicts co-
localization of Olig2 and Ki67 protein expression (b) Bar graph evaluating effect of 
differentiation-promoting dose of AnCoA4: 300nM, BTP2:100nM and SKF96365:300nM 
on OPCs proliferation. Each value (mean ± SEM) was derived from 3 individual 
experiments. One-way ANOVA followed by Dunnett’s test was used for statistical 
comparison. 
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7.2.7 Cell death assessment 
To assess cytotoxicity, compounds were tested against OPCs at differentiation-promoting dose. 
Propidium iodide-based assay (de la Fuente et al. 2015) showed compounds were not toxic to 






















Figure 7.15 Cytotoxicity of the compounds. 
(a) Images representing PI (propidium iodide) staining for the control cells as well as well cells 
exposed to AnCoA4: 300nM, BTP2:100nM, SKF96365:300nM and teriflunomide:3µM for 
~15min. (b) Histogram showing the percentage of dead cells within each treatment group. Each 
value (mean ± SEM) was derived from 3 individual experiments and a total of 30-80 cells. One-
way ANOVA followed by Dunnett’s test was used for statistical comparison. 
 




















































































7.2.8 SOCE alteration in OPCs at differentiation-promoting dose of the compounds 
To investigate whether the compounds can inhibit SOCE at concentrations that promoted 
differentiation, OPCs obtained from 4DIV culture maintained in proliferation medium were 
chosen for single cell Ca2+ imaging experiment. Cells were preincubated for ~15 min with 
compounds at differentiation-promoting dose. SOCE triggered by Tg showed compounds were 





















Figure 7.16 SOCE inhibition through differentiation-promoting dose of the compounds.  
(a) Histograms showing the highest peak SOCE levels triggered by Tg (2µM) in control cells 
and cells pre-treated with BTP2:100nM, and AnCoA4: 300nM. (b) Sample traces representing 
Ca2+ signals to cells with or without pre-treatment of BTP2 and AnCoA4. Each value (mean ± 
SEM) was derived from 3-5 independent experiments done in different days with 60-70 cells. 




SOCE regulates numerous cellular processes, including survival, motility, apoptosis and 
differentiation as well as a critical role in proliferation ( Putney 2005; Kar and Parekh 2013). 
Although Ca2+ is a ubiquitous physiological characteristic of glial cells, but the mechanisms of 
SOCE that is an essential part of Ca2+ signalling in glial cell, particularly in OPCs remain 
uncharacterized.  
Isolation of OPCs 
Several methods for isolation of rat OPCs from the CNS have been developed till date, such as 
immunopanning, fluorescence-activated cell sorting (FACS) by exploiting cell surface specific 
antigens, differential gradient centrifugation or shaking method. In this project, OPCs were 
isolated from neonatal rat brain using two different methods. OPCs isolation was started with 
conventional shaking method, MGC (McCarthy and de Vellis 1980). Later on another newly 
developed OPCs isolation method, MACS procedure (Baror et al. 2019) was introduced. In 
terms of purity, there was no significant difference between the methods, although slightly 
higher purity rate was noticed in OPCs population isolated through MACS procedure (Fig. 
7.1).  
MACS procedure has several advantages over MGC method, former can generate cells much 
quicker than MGC, potentially in a day whereas the latter requires more than a week. Another 
important benefit that MACS procedure could provide is healthy yield of OPCs from neonatal 
to postnatal animal while isolating OPCs from adult brain is more critical when shaking method 
is used.  
Isolated OPCs were then maintained in proliferation medium supplemented with growth 
factors, PDGF and FGF (Calver et al. 1998), on the other hand OLGs were generated through 
growing OPCs in differentiation medium supplemented T3 hormone (Bartel 2004). Usually 4 







SOCE in OPCs 
Activation of SOCE was triggered via both pharmacological (for example, using Tg) and 
physiological (for example, using growth factors) means. SOCE signal was recorded in OPCs 
stimulated by pharmacological mean, Tg. BTP2 and AnCoA4 which are two well-known 
SOCE inhibitors, attenuated such signal (Fig. 7.4), indicating expression of functional SOCE 
channel in OPCs. This agrees with other studies (Paez et al. 2009; Paez et al. 2011; 
Papanikolaou et al. 2017).  
SOCE inhibitors, used in this study, have their own distinct SOCE inhibitory mechanisms. 
BTP2 is well-known to inhibit SOCE but it's mechanism of action remains poorly understood 
and it does not affect Stim or Orai protein individually but may affect their interaction 
(Ishikawa et al. 2003; Zitt et al. 2004; He et al. 2005) whereas AnCoA4 was identified as a 
small molecule that physically bind to fragment of Orai1 protein and was functionally 
characterised to inhibit  Orai1-mediated SOCE (Sadaghiani et al. 2014). These features played 
a great role to identify the target sites in SOCE channel when SOCE was studied on OPCs 
differentiation. 
SOCE was also monitored when triggered by physiological agent; PDGF (Fig. 7.5). Growth 
factor like PDGF, is already known to activate SOCE in OPCs (Paez et al. 2009). PDGF is the 
best characterized and the most active proliferative factor for OPCs. It can interacts with 
receptors tyrosine kinase which then activates Ca2+ signals resultant SOCE activation 
(Taniguchi 1995; Paez et al. 2009). 
Thereafter, teriflunomide, drug for MS and one of the best SOCE inhibitors discovered in this 
study, also tested against SOCE in OPCs. It came as no surprise when SOCE suppression by 
teriflunomide was noted also in OPCs (Fig. 7.6), since the SOCE-inhibitory property of 
teriflunomide was already established to be cell-type independent in early phase of the work 
(Chapter 3).  
Although the best characterised SOCE is well-established to be due to activation of Orai1 
channels (also known as CRAC channels) by Stim proteins, several studies have indicated that 
in some cells, TRPC channels can also be activated by STIM proteins following store depletion 
(Liao et al. 2008; Ong and Ambudkar 2017). So, it is also likely that if a cell expresses both 
Orai and TRPC proteins, the SOCE it would manifest may have Ca2+ entry occurring via both 
the Orai and TRPC channels. It was therefore imperative to assess whether OPCs have 
functional TRPC channels present in their membrane. Previously TRPC mediated Ca2+ entry 
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was characterized in OPCs using pharmacological means, Tg (Paez et al. 2011) however, this 
agent activates both Orai and TRPC- mediated SOCE. Therefore, TRPC- mediated Ca2+ entry 
was characterized using OAG instead of Tg. The former is a membrane permeable, synthetic 
analogue of diacylglycerol (DAG), well known to activate members of the TRPC family of ion 
channels (Hofmann et al. 1999). 
SOCE difference was anticipated between OPCs and OLGs because certain Ca2+ channel 
expression decreases as oligodendrocytes mature (Fulton et al. 2010). However, no discrepancy 
of SOCE signalling noticed between OPCs and OLGs (Fig. 7.8). 
Voltage-gated Ca2+ channel (VGCC) in OPCs 
In addition to SOCE, Ca2+-entry via VGCCs was also characterized in OPCs. Despite of having 
numerous reports on expression of VGCC in oligodendrocytes, there was unsettled argument 
whether OPCs expressed VGCC or not. Studies are available on favour of non-existence of 
this channel in OPCs (Barres et al. 1990; Tong et al. 2009) whilst few other reports their 
existence in OPCs (Fulton et al., 2010; Paez et al., 2010). Such controversy therefore 
encouraged to investigate VGCC mediated Ca2+ entry in OPCs. High dose of KCl evoked 
depolarization have shown the permeability of Ca2+ entry from extracellular environment (Fig. 
7.9) which indicated the expression of VGCC in OPCs. 
 
SOCE in OPCs proliferation 
SOCE, TRPC channel inhibitors as well as teriflunomide have shown to enhance OPCs 
differentiation therefore any effect of these compounds except teriflunomide, on OPCs 
proliferation was explored. Since, teriflunomide was already proven not to enhance 
proliferation (Göttle et al. 2018) therefore it was decided not to investigate this drug further   
on OPCs proliferation. As can be seen in Fig. 7.14, at differentiation- promoting dose, none of 
these inhibitors promoted proliferation although this result contradicted with studies carried 
out by others who have shown SOCE and/or TRPC channel regulate/modulate OPCs 
proliferation (Paez et al. 2009; Paez et al. 2011).  
However current result could be supported by a widely-accepted notion that describes Ca2+ 
channel expression tends to decrease as oligodendrocytes mature (Fulton et al., 2010) which 
again indicated inhibition of such channels could accelerate differentiation process, not 
proliferation.  
 135 
SOCE in OPCs differentiation 
Identification of small molecules, or a signalling pathway that selectively induce differentiation 
of OPCs always have a significant impact on the future treatments of demyelinating disease 
like MS. Despite of having a wide range of effective role on biological process, SOCE was not 
well studied in the context of OPCs differentiation. Present study showed pharmacological 
inhibition of Ca2+-entry via SOCE and TRPC channel potentially upregulated OPCs 
differentiation (Fig. 7.10, Fig. 7.11, and Fig. 7.12). However, others have shown otherwise; 
SOCE and TRPC channel regulate/modulate OPCs proliferation, not differentiation, by golli–
MBP proteins (Paez et al. 2009; Paez et al. 2011). 
It was somewhat surprising to find AnCoA4 being more potent than BTP2 in promoting 
differentiation of OPCs when both are well-established as SOCE inhibitors. This could explain 
whether the inhibitors promoted OPCs differentiation acting through inhibiting the Ca2+ signals 
stemming from the SOCE pathway or inhibiting the protein players underlying SOCE namely 
STIM and Orai.  
To unwrap this puzzle, compounds were tested against SOCE to investigate whether they can 
inhibit SOCE at differentiation-promoting dose, however, neither BTP2 at 100nM dose or 
AnCoA4 at 300nM dose showed any significant effect on SOCE (Fig. 7.16). Such observation 
ruled out the possible effect of Ca2+ signals generated via SOCE on OPCs differentiation and 
hint a possible non-Ca2+ signalling associated role of STIM and/or Orai proteins. AnCoA4 is 
already known to bind to the Orai1 protein at an intracellular site and this explains its ability 
to inhibit SOCE (Sadaghiani et al. 2014) while BTP2 is not experimentally proven to physically 
bind to STIM or Orai protein but is believed to allosterically affect Orai pore geometry only 
when applied extracellularly (Ishikawa et al. 2003; Zitt et al. 2004). Therefore, given the ability 
to promote differentiation and incapacity to inhibit SOCE at differentiation promoting dose, 
both AnCoA4 and BTP2 enhanced OPCs differentiation probably through inhibiting Orai 
protein or blocking the formation of STIM-Orai complex. However, small molecules including 
drugs often have off target effects and this aspect could not be entirely ruled out for the 




The concept of exploring SOCE in OPCs context appeared through teriflunomide, the latter 
was found to block SOCE as well as relevant to MS therefore its effect on OPCs differentiation 
was further investigated. Teriflunomide emerged to promote differentiation at micromolar 
concentration (Fig. 7.1.13). While my study was undergoing, another group published a work 
showing pulsed application of teriflunomide promoted OPCs differentiation (Göttle et al. 
2018). However, present study demonstrated such effect can be achieved at lower dose than 








































8.1 Summary of findings 
Discovering the drug molecules that mimic few known SOCE inhibitors structurally and 
functionally, was one of the major goals of my doctoral study. Using ligand-based in silico 
screening, from existing FDA approved drug library, 10 drugs were selected, and purchased 
followed by testing against SOCE using single cell Ca2+ imaging technique. Out of ten drugs, 
five drugs, namely, leflunomide, teriflunomide, tolvaptan, lansoprazole and roflumilast found 
to inhibit SOCE most at £10 µM dose when tested in RBL-1 cells (Fig. 3.4). Of these 5 drugs, 
roflumilast was the most potent SOCE inhibitor drug with lowest IC50 dose (~4.5µM) (Fig. 
3.5). Drugs also retained their ability to inhibit SOCE in SHSY-5Y cells, indicating that the 
observed effect was not cell type specific (Fig. 3.6). SOCE- inhibitory concentration found in 
this study were achievable from the clinically-used doses of these drugs (table 3.2) which 
makes this finding more significant.  
NFAT translocation assay was then executed to determine whether the chosen drugs could 
affect SOCE-dependent cell signalling and it was satisfying to see their complementary ability 
to retard nuclear translocation of NFAT1(1–460)-GFP in HeLa cells (Fig. 3.10) except 
leflunomide which was proven not to affect NFAT signalling. That could be due to an off-
target effect of leflunomide that requires further experimentation. Whether these drugs had any 
effect on STIM1 oligomerisation and/or STIM1-Orai1 coupling when inhibit SOCE, 
experiments were executed using confocal microscopy with a HEK293 cell line with an 
inducible mCherry-STIM1-T2A-Orai1-eGFP. None of the drugs as well as the known SOCE-
inhibitor BTP2 showed any efficiency on either STIM1 puncta formation or Orai1 puncta 
formation (Fig. 3.11). This indicated that SOCE-inhibitory properties of these drugs could be 
due mechanisms other than STIM/Orai clustering. Of the five drugs, leflunomide and its active 
metabolite teriflunomide are already known to inhibit DHODH enzyme resulting the reduction 
of activated lymphocytes proliferation, therefore these are being used as an immunosuppressive 
drug (Yara and Bidin 2015). The observed SOCE inhibitory properties might contribute 
significantly to the therapeutic benefits of these immunosuppressive drugs. 
Tolvaptan, another drug with SOCE-inhibitory property reveal in this study, is orally and 
intravenously effective non-peptide antagonists for the arginine vasopressin (AVP) receptor 
subtypes. However, tolvaptan is unlikely to affect SOCE at therapeutic doses as the reported 
Cmax of this drug is at sub-micromolar level. Similar to  tolvaptan, omeprazole - a gastric proton 
pump inhibitor, inhibited SOCE at concentration that is much higher than what is possible in 
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clinically used oral doses (Shin and Kim 2013). 
Roflumilast, an orally administered drug, selective inhibitor of PDE4 was the best SOCE 
inhibitor among the 5 drugs found in this study. However, given its known Cmax (Rabe 2011) 
being much lower than what is needed to inhibit SOCE, this drug is unlikely to affect SOCE in 
clinical uses (Rabe 2011).  
With a view to finding agents with more potent SOCE-inhibitory potency, few more 
drugs/compounds from each of the total 4 different pharmacological classes (DHODH 
inhibitor, PDE inhibitors, AVR antagonists and PPIs were purchased and tested against SOCE 
as an extended investigation. Since the best performing drugs inhibited SOCE at ~10 µM dose 
in the earlier studies therefore the goal of the extended study was to find out any drug or 
compound that potentially could inhibit SOCE at concentrations lower than 10µM. However, 
the starting dose for evaluating these molecules were decided to be 10µM so that agents without 
any effect on SOCE at this dose was not considered for testing at lower doses.  
Among the additionally-purchased drugs, none of AVR antagonists and proton pump inhibitors 
(PPI) showed any SOCE suppression at 10 µM dose in RBL-1 cells (Fig. 4.1 and Fig. 4.2). 
Among the PDE and PDE4-specific inhibitors class, only roflumilast N oxide and trequinsin 
supressed SOCE at 3 µM (Fig. 3.4 and Fig. 4.4). From DHODH inhibitor family, vidofludimus 
was found to be the most potent inhibitor of SOCE as it could suppress SOCE significantly at 
nanomolar dose (Fig. 4.9) Thus, as a whole, the follow up work with extended members of the 
4 pharmacological classes led to the finding of three candidates namely trequinsin, roflumilast 
N oxide and vidofludimus as more potent inhibitors of SOCE than the 5 drugs found in the 
early phase of the work. Similar to other drugs with SOCE inhibitory property, all these three 
drugs from extended investigation could suppress SOCE in few other cell types, indicating 
non-cell type specific effect and also in agreement with their effect on SOCE, they could 
significantly retard translocation of the NFAT to the nucleus. Like BTP2 and other initially-
found drugs with SOCE-inhibitory property, the three new drugs also were devoid of any effect 
on STIM-Orai clustering.  
Whether these compounds could affect other Ca2+ signalling pathways, for instances, IP3 
evoked ER-Ca2+ release (Vaughan et al. 1995) or voltage dependent Ca2+ entry (Di Virgilio et 
al. 1987) pathway, were subsequently investigated for . None of the compounds affected these 
channels except vidofludimus which showed some inhibition of IP3 evoked Ca2+ release (Fig. 
5.3).  
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Next, the selected SOCE inhibitors were evaluated for any possible effect on biological 
processes like cancer cell proliferation and neuroblastoma cell differentiation. Cell 
proliferation assay showed tested compounds had diverse effect on lungs cancer cell 
proliferation and such effect was cell type specific (table 6.1). Almost every compound 
inhibited SOCE in lung cancer cells at the dose of anti-proliferation (Fig. 6.2) which indicated 
SOCE inhibitory properties of these compounds might at least partially account for the 
observed antiproliferative effects of these drugs. None of the compounds exhibited any 
differentiation effect when experimented against SHSY-5Y cell (Fig. 6.4). 
The main reason of exploring of SOCE in OPCs was derived from the fact that teriflunomide 
(along with its prodrug, leflunomide) was found to be able to suppress SOCE in immune and 
other cell types at doses that is clinically-achievable. This led to the hypothesis that apart from 
acting on the immune cells and thus reducing inflammation in the periphery as well as in the 
central nervous system, these drugs may also have significant effect on the biology of the 
OPCs. It was therefore logical to first characterise SOCE in OPCs and then evaluate the effect 
of these drugs. The critical aspect of this part of the work was reliable isolation of OPCs in 
good yields. For this, two isolation methods, MGC and MACS were exploited. SOCE was 
observed in OPCs stimulated through both pharmacological and physiological means using 
single cell Ca2+ imaging technique (Fig. 7.4 and Fig. 7.5). Most importantly, no difference in 
SOCE was noticed between OPCs and mature OPCs (Fig. 7.8). In addition to SOCE, voltage-
gated Ca2+ entry was also characterized in OPCs (Fig. 7.9). 
To see the role of SOCE on OPCs differentiation, known pharmacological blockers of SOCE 
and TRPC (also part of SOCE (Liao et al. 2008)) as well as teriflunomide were tested aginst 
OPCs. Result showed pharmacological inhibition of SOCE and TRPC channel potentially 
upregulated OPCs differentiation (Fig. 7.10, Fig. 7.11 and Fig. 7.12) although this result 
contradicted with related existing study (Paez et al. 2009; Paez et al. 2011). Afterwards, these 
compounds were tested to see their role on proliferation, as expected, inhibition of SOCE halted 
OPCs proliferation (Fig. 7.14). This result was believable because in general, Ca2+ channel 
expression tends to decrease as oligodendrocytes mature (Fulton et al., 2010), however, few 




8.2 Future directions 
The key results of this thesis have revealed that some of the FDA approved drugs and their 
analogues could modulate SOCE, additionally, these modulators could inhibit lung cancer cell 
proliferation. Another important aspect of this study was characterization of SOCE in OPCs. 
Further, it was also discovered that pharmacological inhibition of SOCE enhanced OPCs 
differentiation. However, despite of having some important findings from this study, few 
suggestions need to be taken into consideration for further study.  
Firstly, compounds have shown their ability to restrict NFAT translocation into nucleus, Since 
NFAT is important for IL-2 gene expression, as well as also contribute to the expression of 
other cytokines, including IL-3, IL-4, IL-5 (Chow, Rincón, and Davis 1999) therefore it would 
be interesting to see if there any effect these compounds have on cytokines production.  
Secondly, when the compounds were evaluated to see their biological impact, some of the 
compounds have shown anti-proliferative activity on lung cancer cell. Whether the observed 
anti-proliferative effect of these drugs stemmed from their SOCE- modulatory properties or 
inhibition of their known targets or action on any other off target, could not be clearly discerned 
and this need to be investigated in future.  
Thirdly, SOCE was thoroughly characterised in OPCs but expression of SOCE channel 
proteins, STIM, Orai, (Prakriya et al. 2006) remain uncharacterized. Pharmacological 
modulation of SOCE in OPCs led to differentiation which was probably due to inhibition of 
Orai protein that needs to be further investigated through knocking down respective gene.  
Given the SOCE modulatory ability of few PDE inhibitors found in this study, it could have 
been interesting to see the effect of these inhibitors on OPCs differentiation as inhibition of 
PDE4 reported to promote OPCs differentiation (Syed et al. 2013). Recently it was discovered 
that adult OPCs are the cells that are mainly responsible for generating new oligodendrocytes 
during the regenerative process of remyelination (Franklin and Ffrench-Constant 2017) 
therefore OPCs differentiation due to SOCE inhibition found in this study could be re-







Finding the drug molecules that mimic few known SOCE inhibitors structurally and 
functionally, was the major goal of the present study. Using computational and experimental 
techniques, several drugs and their analogues have been found to suppress SOCE significantly, 
with no such prior records. It was interesting to see some existing drugs eventually could 
supress SOCE at clinically relevant doses, therefore any future reuse of these drugs might not 
be required additional study for pharmacokinetic properties as such properties for these agents 
are already been established.  
Aberrant SOCE in various diseases appear to be an attractive therapeutic target for treating 
several diseases. SOCE inhibitors found in this study showed reduced proliferation in lung 
cancer cell which could open a new target to develop therapy for lung cancer.  
Identification of small molecules, or a signalling pathway that selectively induce differentiation 
of OPCs always have a significant impact on the future treatments of MS. OPCs differentiation 
due to pharmacological inhibition of SOCE observed in this study certainly has novelty, which 
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